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PREFACE 
Renal transplantation is the treatment of choice for patients with end-stage renal disease and 
renal transplant recipients have lower rates of morbidity and mortality compared to patients 
remaining on dialysis. Nevertheless, renal transplant patients are considered a high risk 
population and the development of new-onset diabetes after renal transplantation (NODAT) 
may potentiate the risk of reduced patient and graft survival. The main focus of this thesis has 
been to identify renal transplant recipients with NODAT as diagnosed by the current guidelines 
and to explore the association of post-transplant hyperglycemia with long-term mortality in a 
renal transplant population. The thesis includes a large cohort of renal transplant recipients who 
undertook an oral glucose tolerance test (OGTT) performed in the early post-transplant period 
and were observed either until the end of the study or until the occurrence of the primary 
endpoint (death from any cause). 
The lack of medical consensus surrounding the diagnosis of NODAT has resulted in large 
variations in the published incidence figures (5-50%). Although guidelines for the diagnosis 
and management of NODAT have existed since 2003, most studies have not applied the 
diagnostic criteria for diabetes mellitus as suggested by the guidelines. The guidelines for 
NODAT recommend that fasting glucose is the preferred test for diabetes whereas two hour 
glucose after an OGTT may be a more sensitive test. An OGTT is both time-consuming and 
difficult to implement in a clinical practice. Thus a selective screening strategy to identify a 
subgroup of high risk patients to undergo an OGTT could be beneficial. 
 In the early days of renal transplantation steroid doses were high and the incidence of NODAT 
was as high as 50%. New immunosuppressive therapy has evolved during the last few decades 
resulting in reduced total and daily steroid doses. Accordingly, one might expect the incidence 
of NODAT also to have reduced. However, no study has yet verified this hypothesis.  
It is commonly acknowledged that diabetes is associated with increased mortality and 
morbidity after renal transplantation. However, since two hour glucose after an OGTT is more 
6 
 
sensitive than fasting glucose in diagnosing NODAT, we hypothesized that post-challenge 
hyperglycemia might be a stronger predictor of mortality than fasting hyperglycemia. Also, no 
threshold for accelerated mortality risk is known for continuous glucose measurements and we 
examined whether the risk of mortality might be increased even in cases of pre-diabetic levels 
of hyperglycemia.  
Although we have assessed various aspects of early measured glucose variables in the early 
post-transplant period, the studies in this thesis have been of observational design and do not 
explore the possible causal relationship between early post-transplant hyperglycemia and long-
term mortality after renal transplantation. Our goal has rather been to achieve the best possible 
data set and to examine predictors of NODAT and all-cause mortality reflecting the 
associations in a large renal transplant population. 
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Figure 1.  Joseph Edward Murray, a retired 
American plastic surgeon, performed the first 
successful human kidney transplant from an adult 
to his identical twin in 1954. Murray won the 
Nobel Prize in 1990 for work on organ and cell 
transplantation. The photograph is reprinted with 
the kind permission of the Archives of Surgery 
(2). 
BACKGROUND
The first successful kidney 
transplantation (between 
monozygotic twins) was 
performed by Joseph Edward 
Murray in Boston, December 
24, 1954 (Figure 1) (1;2).  
Only two years later the 
surgeon Leif Efskind 
performed the first allograft renal transplantation at Rikshospitalet (3). In 1963, the first renal 
transplantation with a family kidney donor was performed using steroid and azathioprine as 
immunosuppressive therapy. The recipient lived for another 22 years and the donor lived to be 
92 years of age (4).   
 
Immunosuppression, steroids and patient outcome 
Whereas the surgical techniques were available, acute rejections were the main obstacle for 
successful renal transplantation in the early era. Advances in immunosuppression were of 
paramount importance for further progress. The discovery of the immunosuppressive effects of 
the soil fungus cyclosporine A (CsA) in 1969 led to a dramatic turning point in the history of 
organ transplantation. In parallel with the development of new immunosuppressive therapy, the 
improvements in short-term complications after renal transplantation have been substantial, 
possibly due to lower rejection rates and infection control. The current survival rate at one year 
is 95% and around 90% at 3-5 years (5). Renal transplant recipients have increased risk of 
morbibidy and mortality compared to patients with end stage renal disease (ESRD) (6;7), with 
the major causes of mortality being cardiovascular disease (CVD), infectious disease and 
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malignancy (5;8). Although the amount of short-term complications after renal transplantation 
has improved, the long-term results have remained largely unchanged (5;9). 
Over the last decades, kidney transplantation has developed from an experimental procedure to 
the preferred treatment of patients with ESRD (6). The main obstacles to allograft success have 
been the occurrence of acute rejection episodes which in the earliest decades were treated with 
large and repeated doses of corticoidsteroids (10). With the introduction of steroid sparing 
immunosuppressive treatment, such as calcineurin inhibitors, short-term complications 
associated with renal transplantation have improved dramatically (10). However, the 
immunosuppressive therapy has serious adverse effects and may affect risk factors for CVD 
and chronic allograft nephropathy (11;12).  
 
New-onset diabetes after renal transplantation 
Most patients with uremia have abnormal glucose metabolism by mechanism of increased 
insulin resistance (13). Successful renal transplantation is expected to improve glucose 
tolerance by the reduction of uremic toxins. However, subsequent immunosuppression therapy 
after transplantation is associated with glucose intolerance and eventually new-onset diabetes 
after renal transplantation (NODAT) (14). Diabetes mellitus (DM) was described as a 
complication of kidney transplantation over 40 years ago (15). Since the 1980’s the incidence 
of NODAT has ranged between 2 and 53 % across various studies predominantly due to 
differences in diagnostic strategies for diabetes (16-21). In acknowledgement of the need for 
uniformity, international consensus guidelines were established and the diagnostic criteria of 
NODAT have been aligned with the recommendations of the guidelines of The American 
Diabetes Association (ADA) since 2003 (22). Although expert consensus statements for the 
diagnosis of diabetes do not account for the occurrence of diabetes among recipients of organ 
allograft (23;24), non-compliance to the established diagnostic criteria  has been criticized for 
introducing new diagnostic criteria that do not reflect the evidence for developing 
complications of diabetes (25). The NODAT guidelines recommend that fasting plasma glucose 
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(fPG) is the preferred test for diagnosing NODAT, but studies have indicated that a two hour 
glucose (2hPG) after an oral glucose tolerance test OGTT may be more sensitive for the 
identification of NODAT (26;27).  
Since 1995, Rikshospitalet has routinely performed an OGTT ten weeks after renal 
transplantation on recipients without diabetes over 18 years of age. In 1995-96, we observed 
that many of the renal transplant recipients had undiagnosed DM in the early post-transplant 
period. A cross-sectional study confirmed that half the recipients had dysglycemia; either pre-
diabetes (preDM) or DM (28). Although the majority of NODAT cases develop during the first 
three months post-transplant, large epidemiological studies have showed that the number of 
patients developing NODAT increases progressively thereafter (19;29). Notably, in these 
studies NODAT was defined by Medicare claims or by the requirement of hypoglycemic agents 
past 30 days post-transplant. Recent studies report an incidence of NODAT between 7 and 40% 
across various populations and time post-transplant (19;30-36).  
The development of NODAT is classified as a “drug or chemical induced”  or “infectious 
induced” type of diabetes and sorts under the category “other specific types” according to the 
definition and classification of DM of the World Health Organization (WHO) or the American 
Diabetes Organization (ADA) (24;37) (Table 1). There are several similarities between 
NODAT and type 2 DM with both sharing traditional risk factors such as age, ethnicity, family 
history of diabetes, obesity, hyperlipidaemia, hypertension and reduced kidney function. 
Additionally, renal transplant patients are exposed to extensive lifelong immunosuppressive 
medications that are in themselves diabetogenic and put the patients at extra risk of developing 
abnormal glucose metabolism (30;38). Furthermore, renal transplant recipients have 
compromised immune systems and are consequently at risk of opportunistic infections (39). 
Viral infections such as cytomegalovirus (CMV) infections and hepatitis C infections are 
common in transplant patients and have been associated with post-transplant hyperglycemia 
(40;41). 
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Table 1. Etiologic classification of diabetes mellitus 
Classification Etiology 
I. Type 1 diabetes Immune mediated 
Idiopathic 
II. Type 2 diabetes Increased insulin resistance 
Impaired insulin secretion 
III. Other specific types Genetic defects in beta-cell function  
Genetic defects in insulin action 
Diseases of exocrine pancreas 
Endocrinopathies 
Drug or chemical induced 
Infections 
Uncommon forms of immune mediated diabetes 
Other genetic syndromes associated with 
diabetes 
IV. Gestational diabetes During pregnancy 
 
Definitions of glucose categories 
According to the New-onset diabetes after transplantation 2003 International consensus 
guidelines, NODAT should be defined based upon the current definitions of the ADA, WHO, 
and IDF (Table 2) (22). The NODAT guidelines further recommend that an fPG is the preferred 
test for diagnosing NODAT, whereas a 2hPG after an OGTT may identify more NODAT cases.
15
 
 Ta
bl
e 
2.
 D
ia
gn
os
tic
 c
rit
er
ia
 fo
r d
ia
be
te
s a
nd
 p
re
-d
ia
be
te
s b
y 
th
e 
W
H
O
 a
nd
 A
D
A
 fr
om
 1
99
7 
to
 2
01
1.
 T
he
 g
re
y 
ar
ea
s m
ar
k 
th
e 
cu
rr
en
t c
rit
er
ia
 fo
r c
at
eg
or
ie
s w
ith
 
in
cr
ea
se
d 
ris
k 
of
 fu
tu
re
 d
ia
be
te
s.  
 
W
H
O
 
A
D
A
 
 
 
19
99
 
20
11
 
19
97
 
20
03
 
20
10
 
 
N
or
m
al
 g
lu
co
se
 
to
le
ra
nc
e  
 
fP
G
 <
6.
1m
m
ol
/l 
 
A
N
D
  
2h
PG
 <
7.
8m
m
ol
/l 
fP
G
 <
5.
6m
m
ol
/l 
 
A
N
D
  
2h
PG
 <
7.
8m
m
ol
/l 
 
A
N
D
 
H
bA
1c
 <
6,
5%
 
fP
G
 <
6.
1m
m
ol
/l 
 
A
N
D
  
2h
PG
 <
7.
8m
m
ol
/l 
fP
G
 <
5.
6m
m
ol
/l 
 
A
N
D
  
2h
PG
 <
7.
8m
m
ol
/l 
fP
G
 <
5.
6m
m
ol
/l 
A
N
D
  
2h
PG
 <
7.
8m
m
ol
/l 
A
N
D
 
H
bA
1c
 <
5.
7%
 
N
or
m
al
 g
lu
co
se
 
to
le
ra
nc
e  
Im
pa
ir
ed
 fa
st
in
g 
gl
uc
os
e 
fP
G
 6
.1
-6
.9
 m
m
ol
/l 
 
A
N
D
  
2h
PG
 <
7.
8m
m
ol
/l 
fP
G
 6
.1
-6
.9
 m
m
ol
/l 
A
N
D
  
2h
PG
 <
7.
8m
m
ol
/l 
fP
G
 5
.6
-6
.9
 m
m
ol
/l 
 
H
bA
1c
 5
.7
-6
.4
%
 
In
cr
ea
se
d 
ri
sk
 o
f 
di
ab
et
es
 
Im
pa
ir
ed
 g
lu
co
se
 
to
le
ra
nc
e  
fP
G
 <
7.
0m
m
ol
/l 
 
A
N
D
  
2h
PG
 7
.8
-1
1.
0 
m
m
ol
/l 
fP
G
 <
7.
0m
m
ol
/l 
 
A
N
D
  
2h
PG
 7
.8
-1
1.
0 
m
m
ol
/l 
fP
G
 <
7.
0 
m
m
ol
/l 
 
A
N
D
  
2h
PG
 7
.8
-1
1.
0 
m
m
ol
/l 
D
ia
be
te
s m
el
lit
us
 
fP
G
 ≥
7.
0 
m
m
ol
/l 
 
O
R
  
2h
PG
 ≥
11
.1
m
m
ol
/l 
fP
G
 ≥
7.
0 
m
m
ol
/l 
 
O
R
  
2h
PG
 ≥
11
.1
m
m
ol
/l 
O
R
  
H
bA
1c
 ≥
6.
5%
 
fP
G
 ≥
7.
0 
m
m
ol
/l 
 
O
R
  
2h
PG
 ≥
11
.1
m
m
ol
/l 
fP
G
 ≥
7.
0 
m
m
ol
/l 
 
O
R
  
2h
PG
 ≥
11
.1
m
m
ol
/l 
fP
G
 ≥
7.
0 
m
m
ol
/l 
 
O
R
  
2h
PG
 ≥
11
.1
m
m
ol
/l 
O
R
  
H
bA
1c
 ≥
6.
5%
 
D
ia
be
te
s m
el
lit
us
 
16 
 
Diagnostic considerations of new-onset diabetes after renal 
transplantation 
Screening for NODAT? 
The early stages of DM are often asymptomatic and many persons with undetected diabetes are 
thus unaware of their increased risk of morbidity and mortality. Considering the large impact of 
NODAT on patient morbidity and mortality among renal transplant recipients, early identification 
of persons at risk is necessary to implement risk reducing strategies (18;19). Consequently, one 
might consider screening the entire transplant population. In 1968, Wilson and Jungner attempted 
to define generally applicable criteria for medical conditions or diseases that would be suitable 
for screening based upon ethical, social, and  economic considerations as well as the capacity to 
detect the condition at an early stage and the availability of an acceptable treatment (42).  The 
classical screening criteria as defined by Wilson and Jungner is summarized in Table 3 (43). 
The development of NODAT is certainly an important health problem and the natural history of 
the disease is adequately understood. Furthermore, the condition is recognizable at a latent or 
early stage and the facilities of both fPG and 2hPG for the diagnosis are available to a renal 
transplant population. While most renal transplant patients may be positive towards glucose 
testing with an fPG, widespread usage of an OGTT may not be considered an acceptable test to 
the population. One study of more than 6,000 individuals from the general population reported 
that the most important but uncertain variable of screening is the effect of treatment (44). 
Whether or not screening for NODAT is cost-effective is unknown. Although 2hPG identifies 
more NODAT cases, it must be acknowledged that an OGTT may not be feasible to perform in 
all renal transplant recipients. 
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Table 3. Classical screening criteria as defined by Wilson and Jungner (47, 48). 
Criteria 
1. The criterion sought should be an important health problem. 
2. There should be an accepted treatment for patients with recognized disease. 
3. Facilities for diagnosis and treatment should be available. 
4. There should be a recognizable latent or early symptomatic stage. 
5. There should be a suitable test or examination. 
6. The test should be acceptable to the population. 
7. The natural history of the condition should be adequately understood. 
8. There should be an agreed policy on whom to treat as patients. 
9. The cost of case-finding should be economically balanced to expenditure on medical care as a whole. 
10. Case finding should be a continuous process. 
 
Stepwise screening approach: based on risk factors and laboratory analysis 
 It has been suggested that high-risk group, selected by risk factors such as age, sex, and BMI, 
rather than entire populations should be screened for diabetes (45;46). However, a random 
plasma glucose is reported to be superior to age and BMI alone, and comparable to a screening 
model containing age, BMI, ethnicity, sex, and family history of diabetes in a general population 
(47). Alternatively, a stepwise screening algorithm based on laboratory analysis alone may be 
explored. There are three accepted laboratory variables describing a person’s glucose 
metabolism; fPG, 2hPG and glycosylated hemoglobin (HbA1c). Both fPG and HbA1c have been 
included in screening algorithms to detect undiagnosed diabetes in a general population (48;49). 
In a large European epidemiological study, an fPG alone would fail to detect 31% of the subjects 
with a 2hPG ≥11.1 mmol/l. Using a strategy of maximized sensitivity and specificity, this study 
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identified an optimal threshold for predicting a 2hPG ≥11.1 mmol/l of 5.8 mmol/l for women and 
6.4 mmol/l for men with a sensitivity of 76% and 70%, respectively (48). One study found that 
HbA1c of 5.8% or greater yielded the highest sum of sensitivity (86%) and specificity (92%) and 
concluded that an HbA1c of 5.8% would be an appropriate cut-point above which to proceed to 
further evaluation (49). The latter study did not, however, use an OGTT to diagnose diabetes. 
Among patients with ESRD one study found that 8% of the candidates had unknown diabetes 
before transplantation (50). In this study, pre-transplant fPG identified only 16 out of 72 (22%) of 
the cases with undetected diabetes whereas 2hPG after an OGTT revealed another 56 (78%) 
patients with undetected diabetes. The authors suggested a case-finding strategy in which patients 
with an fPG equal to or above 5.1 mmol/l should be referred to a subsequent OGTT for 
verification of the diagnosis of diabetes. This two-step strategy would require half the population 
to undergo an OGTT and identified 90% of the patients with undetected diabetes (50).  
 
The optimal method for diagnosing new-onset diabetes after transplantation: fPG, 2hPG or 
HbA1c?  
According to the current NODAT guidelines, fPG is the preferred diagnostic test for NODAT 
after renal transplantation (22). Renal transplant patients with hyperglycemia often have normal 
fasting glucose and elevated postprandial glucose (26;51). In a study of 200 renal transplant 
recipients, a 2hPG after an OGTT was more sensitive in detecting NODAT and an fPG failed to 
identify 65% of the patients with NODAT beyond 5 months post-transplant (26). Although there 
is a paucity of data in the usage of HbA1c in patients with renal disease, it is logical to assume 
that the validity of HbA1c will decrease with advancing renal failure. The original NODAT 
guidelines of 2003 do not recommend the use of HbA1c for diagnosing NODAT, partly because 
of changes in red cell turnover, anemia, acidosis (22;52). Accordingly, the diagnostic criterion of 
HbA1c ≥6.5% as introduced by the ADA and the WHO may not apply in a renal transplant 
population. A study of renal transplant recipients found that 10% of all patients had an HbA1c 
≥6.1% beyond 3 months post-transplant and the authors suggested that HbA1c should be 
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considered as a screening test for NODAT (53). This study did not, however, include an OGTT 
for diagnosing NODAT.  
 
Risk of new-onset diabetes after renal transplantation 
Most cases of NODAT develop within the first three months post-transplant, but incidences 
increase progressively thereafter (19;29). The pathophysiological mechanisms for NODAT are 
considered to be a combination of insulin resistance and deficient insulin production (54;55). One 
small study comparing the one-year cumulative incidence of NODAT in renal transplant 
recipients with ESRD patients recently showed that 14% and 5% developed NODAT, 
respectively. In this study, only four out of eight recipients with NODAT one year post-transplant 
had pre-diabetes before transplantation, indicating that other transplant associated factors may be 
involved in the development of NODAT (56).  
Risk factors for a disease are important because they help identify asymptomatic individuals who 
have a greater chance of developing the disease in question and may be defined as preceding the 
outcome of disease (i.e. NODAT, a myocardial infarction or death), predicting the outcome and 
being in the biological causal pathway of the disease (57). A biomarker is considered an indicator 
of a biological process that may or may not have a causal relationship with the disease (57;58). 
The difference between a risk factor and a biomarker is subtle; a biomarker may be considered a 
form of risk factor when it is causal. Risk factors and biomarkers for NODAT, which may or may 
not be modifiable, are summarized in Table 4. Increasing age, non-white ethnicity, and 
immunosuppressive medication are the strongest risk factors NODAT (19;21;29;30). 
Components of the metabolic syndrome, physical inactivity, post-transplant viral infections, 
immunosuppressive agents and rejection episodes constitute the target points for reducing the risk 
of progression of post-transplant hyperglycemia into NODAT in the early post-transplant period 
(Table 4).  
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Table 4. Risk factors and biomarkers for new-onset diabetes after transplantation (NODAT) 
after renal transplantation 
 Non-modifiable Modifiable 
Traditional  Age Metabolic syndrome  
Ethnicity  Pre-transplant hyperglycemia  
Gender Post-transplant hyperglycemia 
Family history of diabetes Physical inactivity 
Genetics Social status 
Transplant-related  Cause of ESRD Viral infections 
HLA-mismatch Immunosuppressive agents 
Donor characteristics Rejection episodes 
ESRD; end stage renal disease.  
 
Traditional risk factors for diabetes mellitus 
Increasing recipient’s age is consistently reported to correlate with the incidence of NODAT 
(19;21;28;29). Kasiske et al showed that recipients over 60 years of age had the greatest risk of 
NODAT compared to the reference group of 18-44 years (19). Furthermore, Cosio et al found 
that recipients over 45 years of age were 2.2 times as likely to develop NODAT than recipients of 
a younger age (29). Age is, however, a continuous variable and re-categorizing it may introduce 
unfavorable effects (59;60). In a study of 173 consecutively included renal transplant recipients, 
the risk of NODAT increased by 4% per increased year of age (28). The risk of NODAT is higher 
in non-whites than among white individuals (19;29;30). Also, family history of diabetes is 
reported to increase the risk of developing NODAT by a fourfold if present (28). Furthermore, a 
genetic susceptibility for NODAT has also been demonstrated (61;62) with various genotypes 
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involved. Epidemiological studies have not reported any differences between the genders in the 
development of NODAT (28-30).  
The associations between modifiable traditional risk factors for NODAT are inconsistently 
reported within the literature (18;19;21;28;30;31;33;54;63-67). Pre-diabetes after renal 
transplantation may predict future NODAT; Cosio et al. found that the odds of developing 
diabetes increased by 50% in patients with a fPG 5.6-6.1 mmol/l compared to those with a fPG < 
5.0 mmol/l. Furthermore, 70% of the patients with an fPG 6.1-6.9 mmol/l progressed into 
NODAT within the first post-transplant year (31). Some recipients develop transient abnormal 
hyperglycemia (31;32;68). Indeed, the normalization of glucose intolerance has been associated 
with improved insulin sensitivity (69). On the other hand, an early fPG ≥ 7.0 mmol/l five days 
post-transplant was associated with a fivefold increased risk of subsequent NODAT in a study of 
282 renal transplant recipients  (70).  
Compared to recipients without NODAT, hypertriglyceridemia was particularly pronounced in 
recipients with NODAT in a large single center study of 1,811 renal transplant recipients (18). 
The study also showed that elevated levels of both triglycerides and total cholesterol preceded the 
development of NODAT (18). Hypertriglyceridemia is furthermore associated with insulin 
resistance, a central pathophysiological mechanism in the development of NODAT (71;72).  
Physical inactivity were effective in the prevention and treatment of individuals with insulin 
resistance in a general population and intensive lifestyle modifications improved glucose 
metabolism in a study of 111 renal transplant recipients with impaired glucose tolerance (IGT) or 
NODAT (73;74). Kasiske et al. reported a lower risk of NODAT in recipients with a college 
degree as compared to recipients without a college degree and although not shown within a renal 
transplantation population, it is logical that social status and work related elements such as 
employment and income are associated with increased risk of NODAT (19;75;76).  
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Transplant related risk factors for diabetes mellitus 
Immunosuppressive therapy is a well known modifiable risk factor for NODAT (21). An acute 
rejection episode also strongly predicts the onset of early NODAT and is closely correlated to the 
usage of corticoids (21;29). Furthermore, some studies report that post-transplant viral infections 
might be involved in the pathological mechanisms of developing NODAT, but a causal 
relationship between viral infections and NODAT is not established (77;78). The role of donor 
vital status for the development of NODAT is inconsistently reported in studies (19;79). The 
relationship between ESRD, immunological components and the development of NODAT is 
unclear (21;80;81). 
 
The role of immunosuppressive therapy 
During the early decades of renal transplantation’s history irradiation and high-dose 
glucocorticoid immunosuppressive regimens were used as immunosuppressive therapy to prevent 
acute rejection episode, with steroid induced diabetes reported in up to 50% of renal transplant 
recipients (16;82).  Although corticosteroids are important components of immunosuppressive 
regimens and effectively reduce the incidence of acute rejection, they are also associated with 
numerous adverse effects including hypertension, hyperglycaemia and hyperlipidaemia, cataracts, 
osteoporosis, and CVD (83;84).  The type of immunosuppressive drugs is reported to account for 
74% of the variability of NODAT incidence with prednisolone use considered a predominant 
determinant of insulin resistance after renal transplantation (21;55;85). However, beta cell 
function also seems to be impaired (86). The pathogenesis of NODAT therefore accords with the 
general accepted understanding of the pathogenesis of type 2 diabetes (87;88). Some studies 
suggest that the effects of corticosteroids are dose related (54;69). In a study of 173 renal 
transplant recipients, each increased 0.01 mg/kg/day dose of prednisolone was associated with a 
5% increased risk of developing NODAT (28). In addition, other adverse effects of 
corticosteroids such as changes in weight and redistribution of abdominal fat may also contribute 
to the increased insulin resistance seen after renal transplantation (89;90).  
23 
 
In coherence with an increasing focus on steroid minimization during the past decades and 
steroid withdrawal and lower frequencies of steroid related side effects have been reported in 
recipients receiving steroid-free immunosuppressive therapy (91-93). Improved glucose 
metabolism by way of decreased insulin resistance was seen after corticoid withdrawal at six 
months post-transplant (94). On the other hand, a small study showed that a dosage reduction 
below 5 mg/day was not related to improvements in glucose metabolism (95). Furthermore, 
results of a meta-analysis suggested that steroid avoidance or early withdrawal increased the risk 
of acute allograft rejection (96;97). Although an increasing number of patients are discharged 
with corticosteroids free regimens, a significant proportion of renal transplant recipients return to 
corticosteroids at 6-12 months post-transplant (93). Nonetheless, steroid sparing protocols remain 
controversial and may increase the risk of acute and chronic rejection that in turn may jeopardize 
transplant outcome.  
In addition to corticosteroids, common standard maintenance immunosuppressive protocols 
include calcineurin inhibitors (CNIs) (cyclosporine A and tacrolimus) or mammalian target of 
rapamycin (mTOR) inhibitors which may also contribute to the development of NODAT (35;98-
101). The diabetogenic effects of the commonly used immunosuppressive agents are summarized 
in Table 5.   
CNIs allow lower doses of steroids, but are themselves associated with increased risk of NODAT 
by mechanisms of both impaired insulin secretion and insulin sensitivity (35;54;56;98). 
Tacrolimus is reported to be more diabetogenic than CsA (100;102;103). However, the increased 
diabetogenic effect associated with tacrolimus might be explained by a high whole blood trough 
concentration (C0) of tacrolimus in the early post-transplant period (35;104). A prospective 
randomized study comparing renal transplant recipients treated with either CsA or tacrolimus 
found a higher incidence in the tacrolimus group than in the CsA group at six months post-
transplant (35). In this study the target C0 level of tacrolimus was high (10-15 µg/l) during the 
first three months post-transplant. Another meta-analysis of 4,102 patients included in 
randomized trials comparing patients receiving CsA with tacrolimus indicated that a cut-off point 
for tacrolimus ≤10 μg/l would minimize the risk of NODAT (104). Furthermore, a small study of 
15 renal transplant recipients showed an improved beta-cell secretion capacity after tacrolimus 
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trough level reduction six months post-transplant indicating a possible reversible toxic effect 
(94).   
Table 5. Diabetogenic effects and suspected mechanisms of various immunosuppressive regimens 
Immunosuppressant Diabetogenic effect Mechanism 
Prednisolone +++  Insulin resistance 
Cyclosporine A + 
 Insulin secretion, 
 Insulin resistance 
Tacrolimus ++ 
 Insulin secretion,  
 Insulin resistance 
Sirolimus + 
 Insulin resistance 
Insulin secretion 
Basiliximab (+) Insulin secretion (?) 
Azathioprine - - 
Mycophenolate - - 
+ Denotes graded association with diabetes. - Denotes no association with diabetes. Arrows indicate 
impact on the diabetogenic mechanism 
 
The mTOR inhibitor sirolimus is reported to be an independent predictor of NODAT (99;105). A 
small study of CNI withdrawal and conversion to sirolimus was associated with a 30% increased 
incidence of impaired glucose tolerance and a significant fall in insulin sensitivity (101). 
Impaired glucose metabolism correlates to an increase in serum triglyceride levels (99;101). 
Hypertriglyceridemia is a known side effect of sirolimus (106;107).  
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Recently, one study reported impaired glucose homeostasis in renal transplant recipients 
receiving induction with basiliximab. The authors speculated that basiliximab might interfere 
with the immunologic balance of beta cells in a post-transplant setting and  interfere with the beta 
cell function; however the mechanism for this effect remains unknown (108). Other components 
of standard immunosuppressive regimens are azathioprine and MMF which are considered non-
diabetogenic drugs. Data from the USRDS showed that renal transplant recipients who used 
MMF had an 18% lower risk of developing NODAT compared to recipients who did not (19). 
Furthermore, the absence of an antiproliferative agent was associated with a higher risk of 
developing NODAT (20).  
 
The link between viral infection and new-onset diabetes after renal transplantation 
Renal transplant recipients use extensive doses of lifelong immunosuppressive medication and 
are thus at risk of serious and opportunistic infectious diseases.  The CMV is a beta-herpes virus 
that is transmitted through infected body secretions and may affect several organs. Infections 
with CMV are highly prevalent early after renal transplantation and correlate with post-transplant 
morbidity and mortality (109;110). Some studies have hypothesized a linkage between early 
onset CMV infection and NODAT (40;111). A study of 160 non-diabetic renal transplant 
recipients showed an association between NODAT and both CMV disease and asymptomatic 
CMV infection (40). In this study, insulin sensitivity was not affected by CMV infection, 
indicating that impaired insulin secretion might be involved in the impaired glucose metabolism 
seen in recipients with CMV infection (40). Conversely, a retrospective analysis of 1,023 Indians 
transplanted between 1989 and 2000 showed no association between CMV and NODAT (112). 
The mechanisms of a correlation between virus infections and diabetes progression are poorly 
understood. One in vitro study of the general population showed a direct deleterious effect of 
coxachie virus on beta cell survival resulting from a virus induced activation of proinflammatory 
cytokines (113).  The following explanations for beta cell damage by concurrent CMV infection 
have been proposed: 1) a direct toxic effect by the CMV with subsequent apoptosis, 2) indirect 
effect by a inflammatory response of cytokine production either by the beta cell itself (autocrine 
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effect) or by other islet cells such as endothelial cells or fibroblasts (paracrine effect) ultimately 
leading to apoptosis of the beta cells, or immunological mechanisms involving either a cytokine 
response by circulating macrophages or granulocytes or a specific T-cell response reacting with 
the beta cells (77). However, no causality between CMV infection and NODAT has been 
established.  
Hepatitis C virus (HCV) has been associated with DM in the general population (114). The 
relationship between HCV and NODAT is inconsistently reported in studies. Some studies have 
shown a positive correlation between HCV and NODAT (19;115;116), whilst others have not 
(117). Two studies hypothesized that the diabetogenic effect of tacrolimus might be enhanced by 
an underlying hepatitis C infection (41;78). The current guidelines for NODAT recommend that 
management of HCV should be coupled with monitoring and prevention of diabetes after renal 
transplantation, particularly in HCV-infected patients (22).  
 
Impact of early post-transplant glycemia on long-term outcomes 
The development of NODAT is well recognized as a complication of organ transplantation. 
Large epidemiological studies have shown that NODAT adversely affects long-term patient 
survival (18;19;118). Data from the USRDS showed that renal transplant recipients with NODAT 
had a two-fold increased risk of all-cause mortality compared to recipients with normal glucose 
tolerance (NGT) (19). Cosio and et al. analyzed data from 1,811 renal transplant recipients in a 
single centre study between 1983 and 1998 and found that from the time of the NODAT 
diagnosis, the mortality risk of recipients with NODAT was comparable to the risk of pre-
transplant DM (18). On the other hand other studies have shown no association between NODAT 
and reduced patient survival (119;120). In a large study including 37,448 renal transplant 
recipients, pre-transplant DM, but not NODAT, was the major predictor for all-cause and CV 
mortality one year after transplantation (120). However, since this study had a relatively short 
observational time, it may have been subject to a statistical type II error. One study reported that 
pre-transplant diabetes was the major predictor of all-cause and cardiovascular (CV) mortality 
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whereas NODAT alone was not associated with patient survival (120). Importantly, none of these 
epidemiological studies used glucose testing to diagnose NODAT as is recommended by the 
current guidelines. The different methods by which NODAT is diagnosed may contribute to the 
diversity in long-term outcome reported in these studies (22). 
Whether diabetes duration is associated with long-term mortality outcome is unclear. One study, 
however, showed that recipients with NODAT had similar patient survival estimates as those 
with preexisting DM from the time of the NODAT diagnosis, suggesting that patients with 
NODAT may have an accelerated progression of diabetes related complications (18). In this sub-
analysis, the authors did not adjust for known confounders for mortality. Although the recipients 
with pre-existing DM and NODAT were of comparable age (47.5 vs. 48, respectively), the 
proportion of males and African Americans was higher among recipients with NODAT than pre-
existing DM (63% vs. 60% and 28% vs. 24%, respectively) (18). 
Renal transplant recipients with NODAT have also been linked to increased rates of CVD as 
compared to recipients with NGT (18;31;119). Conversely, the influence of NODAT on graft 
survival is unclear. Data from a large US database found a 63% (46-84%) increased risk for 
overall graft failure and a 46% (25-70%) increased risk of death-censored graft failure as 
compared to recipients without NODAT (19). This study did not, however, adjust for acute 
rejections as a confounding variable in the multivariable analysis. Furthermore, another study 
using the same database found an association between NODAT and overall graft  failure (HR 
1.24 [95% CI 1.14-1.35]) but not after censoring for death with a functioning graft (1.12 [0.99-
1.26]) (121). Renal transplant recipients who experienced an acute rejection episode and 
developed NODAT had the greatest risk of transplant failure (121). One study also reported that 
acute rejection had greater impact on 15-year graft survival and death censored graft survival 
than NODAT (122). Thus, although NODAT probably has a detrimental effect on patient 
survival after renal transplantation, the influence of NODAT on graft survival after censoring for 
death with a functioning graft needs further clarification. 
Although 2hPG after an OGTT is shown to be superior to an fPG in the detection of NODAT, the 
long-term implications of abnormal post-prandial glucose measurement in renal transplant 
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recipients are unknown. In the general population, epidemiological studies suggest a close link 
between post-prandial hyperglycemia and CVD (123;124). Underlying mechanisms for this 
relationship includes oxidative stress and glycosylation of proteins leading to endothelial 
dysfunction (125). Recent studies have further suggested that fPG correlates non-linearly, 
whereas both 2hPG and HbA1c correlates linearly with CVD and mortality (126-129). The 
relationship between non-diabetic hyperglycemia and mortality is not well studied among renal 
transplant recipients. However, Cosio et al. reported a strong association between fasting 
hyperglycemia and CV risk post-transplant suggesting that there is a continuous relationship 
between increasing levels of fasting plasma glucose and CV-risk (31). 
In the general population both prediabetic glucose categories (impaired fasting  glucose [IFG] 
and especially IGT) are associated with CVD and mortality (123;130-132). In a renal transplant 
population, similar data on pre-diabetic categories are limited. In a sub-study of 490 adult renal 
transplant recipients, a total of 351 renal transplant recipients with post-transplant fasting 
hyperglycemia were followed for an average period of 40±14 months (31). Compared to having 
an fPG <5.0 mmol/l, an fPG between 5.6 and 6.0 mmol/l was not correlated with increased CV 
risk, but recipients with an fPG between 6.1 and 6.9 mmol/l had a 2.4 times increased risk of any 
CV events compared to recipients with fPG <5.0 mmol/l (31). 
 
The main research questions addressed in this thesis 
In this thesis, the validity of fPG and HbA1c, using a 2hPG ≥11.1 mmol/l as the reference, for 
diagnosing NODAT was assessed in a renal transplant population. Furthermore, we examined 
whether the incidence of NODAT was reduced in line with changes in the immunosuppressive 
therapy. Finally, the impact of hyperglycemia on long-term mortality outcome after renal 
transplantation was examined. 
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AIMS OF THE STUDIES 
Paper 1 - Screening for new-onset diabetes after renal transplantation 
The aim of this study was both to validate fPG and HbA1c for the diagnosis of NODAT defined 
by a 2hPG ≥11.1 mmol/l and to evaluate a two step screening algorithm to select patients for an 
OGTT based on laboratory values for either fPG or HbA1c. 
 
Paper 2- Reduced incidence of new-onset diabetes after renal 
transplantation 
The aim of this study was to examine whether glucose tolerance measured early post-transplant 
had improved in parallel with changes in immunosuppressive therapy introduced in 2001. 
 
Paper 3 - Association of post-transplant glycemia with mortality 
The aim of this study was to assess the long-term effects of early post-transplant glycemia on 
long-term mortality after renal transplantation. 
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 MATERIAL AND METHODS 
Patients and study designs 
Since May 1995, The Laboratory of Renal Physiology, Rikshospitalet has routinely examined the 
majority of non-diabetic renal transplant recipients over 18 years of age with an OGTT ten weeks 
after renal transplantation, thus providing a large cohort of renal transplant recipients available 
for follow-up studies. A mandatory OGTT was performed during the pre-transplant work-up in 
the majority of study patients to exclude recipients with pre-existing DM before transplantation. 
In a sub-group of 301 patients transplanted between October 2003 and October 2005 (new cohort, 
paper 2), 79% reported a complete OGTT before transplantation at a median of 50 (range 32-82) 
weeks before transplantation in the period 2003-2005 (64). 
The studies included in this thesis had a prospective observational design starting at the time of 
transplantation. A total of 2,458 renal transplantations were performed between February 2nd 
1995 and October 19th 2006 (Figure 2). Recipients under 18 years of age (n=102), recipients who 
had preexisting diabetes at the time of transplantation (n=366), recipients who experienced either 
graft loss (n=63) or died (n=49) before the scheduled OGTT were not included in the study. A 
total of 241 (10 %) recipients were unable to perform an OGTT at ten weeks post-transplant. The 
main reason was early transfer of these patients to local hospitals due to comorbidity. The 
recipients who were unable to perform an OGTT ten weeks after transplantation were on average 
older (50 [SD 15] and 55 [16] years, P<0.001) and more likely to receive a kidney from a 
deceased donor (75% vs. 58%, P<0.001) compared to recipients included in the studies. 
Consequently, by exclusion of these patients the mortality risk might have been underestimated 
in the transplant population examined in this thesis. The proportion of males was similar in both 
groups (no OGTT: 65% and study population: 66%, P=0.885).  
The participants were predominantly Caucasians and the majority of the recipients were hepatitis 
C negative.  
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Figure 2: The study population included in the thesis. For paper 1 a total of 1,636 eligible renal transplants 
were included. For paper 2, a total of 494 out of 1,636 eligible patients were included. For paper 3, re-transplant 
candidates were excluded leaving a total of 1,410 renal transplants to be included in the study.  
Renal transplants
1995-2006
n=2,458
Eligible
n=1,637
Manifest NODAT
n=58
OGTT
n=1,352
Paper 3
n=1,410
Retransplant candidates
n=227
Non eligible
n=821
Paper 2
n=494
Paper 1
n=1,637
Historical cohort
1995-96
n=173
New cohort
2004-05
n=321
Manifest PTDM
n=66
OGTT
n=1,571
fPG ≥7.0 mmol/l
n=104
fPG <7.0 mmol/l
n=1,467
HbA1c missing
n=538
HbA1c available
n=929
Not included
n=1143
 
All patients gave informed consent to participate and the studies were approved by the regional 
ethics committee (S-07485a). 
 
Paper 1 – Screening for new-onset diabetes after renal transplantation 
For the study of screening for NODAT the outcome data was collected at ten weeks post-
transplant. Patients receiving their first renal allograft and patients who were re-transplanted were 
included (n=1,571) whereas patients who developed NODAT during the first ten weeks after 
transplantation were excluded (n=66) (Figure 2). 
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Paper 2 – Reduced incidence of new-onset diabetes after renal transplantation 
For the study of NODAT incidence, outcome data were collected prospectively ten weeks post-
transplant. We compared a new cohort of recipients transplanted in 2004-05 with a historical 
cohort transplanted in 1995-96 which introduced retrospective elements in the study design. We 
included both patients who received their first renal allograft and those who were re-transplanted 
(Historical cohort: n=173 and New cohort: n=321) (Figure 2). 
Paper 3 – Association of post-transplant hyperglycemia with mortality 
In the study of the association of post-transplant glycemia on long-term survival, only first time 
renal transplant recipients were included (n=1,410). Data collected at the ten week visit was used 
as baseline data for the prospective survival analysis observing the recipients until either the 
primary endpoint (death) was reached or until December 2008 (Figure 2).  
 
Immunosuppressive therapy 
From February 1995 to January 2000, the standard immunosuppressive protocol consisted of 
prednisolone, cyclosporine (CsA) and azathioprine. Induction therapy with basiliximab in 
combination with CsA and prednisolone was used in 2000, and from January 2001, the standard 
immunosuppressive protocol included prednisolone, CsA and mycophenolate, without induction 
therapy. Tacrolimus was given mainly if CsA was withdrawn due to rejection, toxicity or side 
effects. Steroids were given in doses of 500 mg methylprednisolone i.v. during surgery followed 
by a dose of 80 mg i.v. the following day. Oral prednisolone was given in a daily dose of 80 mg 
from day 2, tapered to 15 mg after one month and ten mg after two months. CsA was given orally 
in doses of 5 mg/kg on the day of transplantation and another 5 mg/kg i.v post-operatively. CsA 
was subsequently given orally ten mg/kg in two daily doses and titrated according to blood CsA 
concentration levels. The CsA monitoring was initially titrated according to C0 of 300-400 µg/l, 
tapering to 100-150 µg/l at ten weeks post-transplant from 1995 thru 2002 and according to two 
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hour post-dose concentration (C2) initially targeting 1600-2000 µg/l, tapering to 1200-1700 µg/l 
at ten weeks post-transplant from 2003 thru 2006. Tacrolimus was titrated according to C0 during 
the entire study period: initially targeting 10-12 µg/l, tapering to 5-10 µg/l at ten weeks post-
transplant. The patients received azathioprine in an average dose of 1 mg/kg/day. Mycophenolate 
was used twice daily in standard doses of 1,000 mg. 
Acute rejection episodes were diagnosed clinically and biopsies were as a rule performed for 
verification. Rejection episodes were treated with intravenous methyl prednisolone boluses (500-
125 mg/day) for 4-5 days. The oral daily dose of prednisolone was subsequently increased to 30 
mg and then tapered by 5 mg every 2 weeks. Biopsy-verified steroid resistant rejections were 
treated with antilymphocyte antibodies (ATG/OKT3). 
 
Glucose measurements 
Oral glucose tolerance test 
The OGTT was performed after an overnight fast with patients instructed not to eat or drink, to 
refrain from smoking and to not take any medication less than eight hours before the test. Each 
patient drank75 g of anhydrous glucose dissolved in 250 ml of water. Blood samples were drawn 
after 0 and 120 minutes. From May 1995 to August 1996, glucose was measured in serum using a 
glucose dehydrogenase method (Cobas Mira, Roche, Basel, Switzerland). Theoretically, a longer 
pre-analytic time lapse from blood sampling till processing may permit a continued intracellular 
glucose metabolism and thus lower glucose concentrations in serum. However, the differences in 
glucose values in plasma and serum are shown to be small and we have presented the glucose in 
serum and plasma as equivalent values (133).  From September 1996 until December 2006 
venous whole blood glucose was measured immediately after sampling using the Hemocue AB 
B-glucose Analyzer, Angelholm, Sweden. Because glucose permeates the erythrocytes quickly, 
the glucose concentration is higher in plasma than in blood. A conversion factor between venous 
blood and plasma is approved in normally hydrated individuals (134). Thus, we multiplied blood 
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glucose with the conversion factor of 1.11 to calculate the plasma glucose (134). Internal quality 
assessment was based on daily management of precision at the lowest (2.5[0.8] mmol/l) and 
highest levels (10.0[1.2] mmol/l) of venous blood glucose. External quality assessment applied 
every 6 months resulted in an interassay coefficient of variance of 5 %. 
The OGTT was performed once without a confirmatory test on a subsequent day as 
recommended by the current guidelines. For clinical usage a repeated diagnostic test is 
recommended (37). However, the WHO acknowledge that for epidemiological purposes, the 
diagnosis of diabetes may be based on a single OGTT or fPG (135). Furthermore, fPG and 2hPG 
are reported to have intraindividual coefficients of variance of 13% and 7%, respectively in 
Caucasian subjects with newly diagnosed DM (136). Although the OGTT test is more time 
consuming and has a higher intra-individual coefficient of variance compared to fPG, a 2hPG is 
more sensitive for the detection of NODAT and necessary for the identification of IGT after renal 
transplantation (26;27).  
 
Glycosylated hemoglobin – HbA1c 
HbA1c (normal range 3.5-6.5%) was measured by a Diabetes Control and Complication Trial 
(DCCT)-aligned turbidimetric immunoinhibition (Tina-Quant II HbA1c Assay, Roche, Basel, 
Switzerland), using an auto-analyzer Hitachi 917 or Modular P. Precisions of the lowest and 
highest levels of HbA1c were 6.3% (coefficient of variance 2.8%) and 10.7% (coefficient of 
variance 2.3%), respectively. External quality assessment showed less than 3% deviation from 
the target. 
In Norway, High Performance Liquid Chromatography (HPLC) assay and immunological 
methods are commonly used for HbA1c measurements (137). The immunological method used 
for the analysis of HbA1c is less affected by variant hemoglobin than chromatographic methods 
(138;139). The Tina-quant II HbA1c antibody recognizes the glycosylated N-terminal part of 
betaglobin. Most variant hemoglobin has mutations located either in other parts of betaglobin 
35 
 
than recognized by this antibody or in alpha globin. Variant hemoglobin is rare in our renal 
transplant population, which consists of 95% Caucasians (140). Because of the low prevalence of 
variant hemoglobin and the immunological method’s ability to withstand interference from 
variant hemoglobin, the number of possible variant hemoglobin is minimal and should not have 
influenced the results in this thesis. Chemically modified derivates, such as carbamylated 
hemoglobin (cHb), are increased in uremic patients and may falsely overestimate HbA1c (139). 
However, in our study, however, HbA1c was measured by enzyme immunoassay which is not 
influenced by hemoglobin carbamylation (139;141). Nevertheless, ten weeks after renal 
transplantation the renal function of the study participants was stabilized (mean urea 9.7 [SD 4.2] 
mmol/l).  
Pathophysiological conditions affecting red cell turnover limit the utility of HbA1c in the 
management of glucose metabolism (139). Most patients scheduled for renal transplantation are 
treated with erythropoietin which increases erythrocyte turnover and consequently reduces 
HbA1c. The widespread use of erythropoietin for dialysis patients and patients with chronic renal 
disease has minimized the degree of anemia in patients who are scheduled for renal 
transplantation (142). Accelerated red cell turnover probably contributes to a lower HbA1c at the 
time of transplantation. Early after transplantation, blood loss related to the surgical procedure 
and subsequent inflammation may lead to anemia. Furthermore high doses of immunosuppressive 
therapy causing bone marrow suppression, and the subsequent cessation of erythropoietin 
substitution may delay the normalization of erythrocyte turnover (142). Thus, given the short 
diabetes duration and a lower HbA1c at the time of transplantation, HbA1c cut-off for identifying 
diabetes might be lower in a transplant population compared to the general population. On the 
other hand, normalized levels of erythropoietin and hematocrit have been reported as early as two 
months post-transplant (142). 
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Viral infections 
Data on CMV infection and HCV infection were retrieved from the patients’ records in the 
microbiology department during the first ten weeks after transplantation. 
 
Cytomegalovirus infection 
All renal transplant recipients undergo weekly testing for CMV infection during the first ten 
weeks. From May 1995 to 2002 CMV was assessed by virus isolation in blood by measuring 
CMV pp65 antigen lower matrix protein in EDTA blood samples. The results was given as the 
number of CMV pp65 antigen-positive cells per 100 000 leukocytes. Patients with CMV pp65 
antigenaemia of 1 or more per 100,000 leucocytes were classified as having CMV infection 
(143).  Separated leucocytes (cytospins) of EDTA blood were strained for CMV pp65 by an 
immunocytochemical method and used for quantification. From 2002, assessment of CMV DNA 
in plasma was performed by a quantitative CMV DNA PCR (Cobas Amplicor CMV Monitor®, 
Roche Diagnostics, Basel, Switzerland). The CMV PCR has been shown to be highly predictive 
of future CMV disease (144).  
 
Hepatitis C virus infection 
The presence of antibodies to HCV was assessed by a third-generation enzyme immunoassay 
(Axzym HCV 3.0; Chiron, Emeryville, California, USA). The majority (99%) of the renal 
transplant recipients at our centre were hepatitis C negative. Consequently, we have not included 
hepatitis C as a potential confounder for NODAT in the studies in this thesis. 
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Glucose tolerance criteria used in this thesis 
Paper 1 – Screening for new-onset diabetes after renal transplantation 
The 2003 ADA criteria for the diagnosis of diabetes, which coheres with the WHOs criteria of 
1999, were employed in paper 1 (24;145). We defined a 2hPG ≥11.1 mmol/l as the “golden 
standard” for the detection of diabetes and the diagnostic criteria of fPG ≥7.0 mmol/l was 
validated using 2hPG ≥11.1 mmol/l as the reference. In 2010, the ADA introduced HbA1c≥6.5% 
as an additional diagnostic criterion for diabetes in the general population; some six months after 
the publication of paper 1 (37). The newly introduced criteria were validated against the reference 
(2hPG ≥11.1 mmol/l) in a posthoc analysis of data of a subgroup of 976 consecutive renal 
transplant recipients who underwent an OGTT ten weeks after renal transplantation. 
Paper 2 – Reduced incidence of new-onset diabetes after renal transplantation 
In paper 2, the WHOs 1999 criteria for the diagnosis and classification of diabetes and preDM 
was used to classify glucose measurement into glucose categories (24). Since the historical cohort 
was categorized according to the WHO criteria, we used the WHO criteria for the assessment of 
glucose intolerance in the new cohort. The glucose measurements from the historical cohort of 
1995-96 were re-categorized according to the WHO criteria of 1999 (24).  
Paper 3 – Association of post-transplant hyperglycemia with mortality 
In paper 3, we explored the association of diabetes and pre-diabetic categories with long-term 
mortality using continuous glucose measurements and the current ADA criteria for glucose 
categories (Table 2) (145). In order to explore potential differences between the ADA and WHO 
guidelines, the analysis was additionally performed with glucose measurements categorized 
according to the WHO-criteria (24).  Furthermore, the patients were categorized as either post-
challenge hyperglycemic defined as a 2hPG≥7.8 mmol/l or normoglycemic defined as a 
2hPG<7.8 mmol/l. 
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Registry data; covariates and outcome data 
There is only one center which performs renal transplantations in Norway. Pre-transplant work-
up, as well as post-transplant follow-up beyond 3 months, is handled by local centres, whereas 
the national transplant center handles the renal transplant recipients from the time of 
transplantation until transferral to local units approximately three months after transplantation. 
 
Laboratory of Renal Physiology 
Since 1995, the majority of renal transplant recipients have undergone a routine laboratory 
examination ten weeks after transplantation, including an OGTT, before being transferred to local 
units, at the Laboratory of Renal Physiology. Ten weeks post-transplant, the majority of renal 
transplant recipients is clinically stable and immunosuppressive therapy has been reduced to 
maintenance levels. The following data was retrieved from the database of the Laboratory of 
Renal Physiology:  
Paper 1: Explanatory variables: fPG, HbA1c, age, gender, height, weight, Cr-EDTA measured 
glomerular filtration rate (GFR), donor vital status. Outcome variables: NODAT defined by 
2hPG. 
Paper 2:, Explanatory variables: age, gender, height, weight, donor vital status, CNI usage (CsA 
and tacrolimus), doses and trough levels of CsA, prednisolone dose. Outcome variable: NODAT 
defined by fPG and 2hPG. 
Paper 3: Explanatory variables: fPG, 2hPG, NODAT, IGT, IFG, age, gender, height, weight, 
serum creatinine, Cr-EDTA GFR, donor vital status, serum lipid levels (total cholesterol, high 
density cholesterol, triglycerides), CNI usage (CsA and tacrolimus), doses and trough levels of 
CNI (CsA and tacrolimus), prednisolone dose.  
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Furthermore, to obtain the best possible baseline dataset for paper 3, we searched the patient 
records for missing data on serum lipid levels, creatinine and HbA1c. 
 
The Norwegian Renal Registry 
The Norwegian Renal Registry was formally constituted in 1994 as a collaboration between The 
Norwegian Renal Association and Oslo University Hospital, Rikshospitalet (146). Further, 
Norwegian renal units have reported to the ERA-EDTA-registry since the late sixties. Of the 19 
counties in Norway, all but one has a central renal unit and some have two units reporting data to 
the Norwegian Renal Registry. Nephrologists at 24 centres annually report data on all Norwegian 
patients undergoing renal replacement therapy to the registry which contains data on all 
cardiovascular events such as cardiovascular procedures (cardiovascular surgery or percutaneous 
coronary intervention), myocardial infarction, strokes, graft failure and death. The numbers of 
death were cross-checked with the official National Census and the causes of deaths were 
encoded by experienced local nephrologists. Additional variables such as HLA-B27, rejection 
episodes, methylprednisolone doses, causes of ESRD, blood pressure, antihypertensive 
medication, smoking habit, pre-transplant dialysis (months on dialysis) are registered in the 
database. The following data was extracted from the Norwegian Renal Registry:  
Paper 2: Explanatory variables: HLA-B27, total methylprednisolone dose, polycystic kidney 
disease, 
Paper 3: Explanatory variables: pretransplant CVD, blood pressure, usage of antihypertensive 
medication, smoking habit (never, active, former), pre-emptive transplantation, months on 
dialysis before transplantation, early rejection episodes (during the first ten weeks post-
transplant). Outcome variables: mortality figures and causes of death. 
The results of this thesis were partly based on register analysis, and the validity of our data is 
therefore a reflection of the quality of the registers involved. Each register may only be used to 
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describe the occurrence of the events in the studies, and not to provide any causal relationships 
between the explanatory variables and the events. 
 
Statistical analysis 
Descriptive data are presented as mean (standard deviation [SD]), median (range) or frequencies 
(%). Differences between groups were analyzed using independent samples t-test or one way 
analysis of variance (ANOVA) for continuous data and chi-square test or Fishers’s exact test for 
categorical data.  Correlations were calculated with Pearson’s correlations coefficient for 
parametric variables and Spearman’s Rho for non-parametric variables. Risk estimates were 
presented as Odds Ratio (OR) or Hazard Ratio (HR) with 95% CI as appropriate. For all analyses 
a two tailed P<0.05 was considered significant. The analyses were performed using SPSS 
(Chicago IL, USA) (version 12 and 15), PASW 18 (Chicago, IL, USA) and STATA11.0 
(StataCorp, College Station, TX, USA). 
 
Categorization of data 
Observational epidemiology aims to assess relationships between predictors and disease 
outcomes using appropriate statistical methods. Categorization of continuous data into ordinal 
variables (i.e. per ten years of age) or dichotome variables (i.e. above v.s. under 60 years of age)   
are common, but may result in several problems (147). First, valuable information and statistical 
power may be lost and categorization of data may bias the final results. (59;60). Second, arbitrary 
cut-offs may result in an overestimation of outcome variation between categories. Thus, 
individuals close to each other but on opposite sides of the cut-point (i.e. 39 years of age vs. 41 
years of age with a cut-point of 40 years) are characterized as being very different rather than 
being very similar (60). Third, a non-linear relationship between a predictor and the outcome may 
be concealed (59;60). In view of this, we included glucose measurements three different types of 
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variables: 1) continuous variables, 2) categorized variables according to the ADA (PTDM, IGT, 
IFG, and NGT), and 3) dichotomized variables according to the level of 2hPG (post-challenge 
hyperglycemia [2hPG ≥7.8 mmol/l]) and normoglycemia [2hPG <7.8 mmol/l]) 
 
Receiver operating characteristic analysis 
Receiver operating characteristic analysis 
was originally developed during World 
War II to analyze classification accuracy in 
differentiating signals from noise in radar 
detection (148). The ROC plots are 
commonly used to select a cut-off point to 
distinguish “normal” from “abnormal”, and 
to investigate to what extent the test results 
differ among people who do or do not have 
the diagnosis of interest (149). The 
diagnostic accuracy of the test is given by 
the area under the curve (AUC). An AUC 
of 1 equals a perfect prediction of the 
diagnosis (line A) whilst an AUC of 0.5 
(equals the 45 degree reference line) 
indicates that the test randomly predicts the 
diagnosis of interest (Figure 3). As the diagnostic test accuracy improves, the ROC curve moves 
towards A (Figure 3). It has been suggested that an AUC greater than 0.9 has high diagnostic 
accuracy, levels between 0.7-0.9 indicate moderate accuracy, 0.5-0.7 low accuracy 
 and 0.5 indicates a chance result (150). Figure 3 demonstrates schematically different levels of 
diagnostic accuracy by various AUCs. 
Figure 3. Hypothetical receiver operating 
characteristic (ROC) curves representing different 
levels of diagnostic accuracy by areas under the 
curve (AUCs). 
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The properties of a diagnostic or screening test are often described using sensitivity and 
specificity or predictive values (151;152). Likelihood ratios are ratios of probabilities and may be 
used as alternative statistics for summarizing diagnostic accuracy (153). Each test has its own 
likelihood ratio which summarizes how many times more likely patients with the disease are to 
have that test-result than patients without the disease. A likelihood ratio greater than 1 indicates 
that the test result is associated with the presence of the disease (positive likelihood ratio) 
whereas a likelihood ratio less than 1 indicates that the test result is associated with absence of 
the disease (negative likelihood ratio). The further the likelihood ratio is from 1, the stronger the 
evidence for the presence or absence of the disease. A likelihood ratio higher than ten or lower 
than 0.1 is considered strong evidence upon which to confirm or rule out a diagnosis of interest 
(153). Statistical measures descriptive of diagnostic accuracy are explained in Table 6.  
There are different approaches to choosing a cut-point which determines whether a disease is 
present or not. If both sensitivity and specificity are equally important for the binary outcome, the 
optimal cut-point is identified by the point on the curve closest to the upper left hand corner 
(maximized sensitivity and specificity) (149;154). Another statistical approach is to choose the 
point on the curve with the maximum vertical distance from the 45-degree reference line 
(Youden index) (155). The choice of the cut-point that optimizes the utility of the test is often an 
expert opinion taking factors such as the sensitivity, specificity, cost and purpose of the test into 
account (154). Sensitivity and specificity are both measures of a test’s performance, but provide 
distinct and equally important information. Sensitivity provides information on how often the test 
is positive in diseased persons, whereas specificity provides information on how often the test is 
negative in non-diseased persons (156).  
A single test, such as fPG, may be used for both screening and diagnostic purposes, but different 
cut-points may be involved. In a highly sensitive test, a positive test result may be used to 
identify patients with increased risk of the disease. On the other hand, when an fPG is used for 
diagnostic purposes, the aim of the test would be to exclude subjects without the disease 
(154;156). In our study, we argue that for screening purposes in the early post-transplant period, a 
cut-point with a maximized sensitivity should be chosen and that a minimum of 80% sensitivity 
for diagnosing NODAT would apply for a screening test in a renal transplant population. 
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Table 6 
Term Explanation 
Sensitivity The proportion of true positives that are correctly identified by the test (151).  
Specificity The proportion of true negatives that are correctly identified by the test (151).  
Positive predictive value 
The proportion of patients with positive results who are correctly diagnosed 
(152). 
Negative predictive value 
The proportion of patients with negative test results who are correctly 
diagnosed (152). 
Positive likelihood ratio 
The ratio of the probability of a positive test in people who do have the disease 
to the probability of the same result in people who do not (153).  
Negative likelihood ratio 
The ratio of the probability of a negative test in people who do have the 
disease to the probability of the same result in people who do not (153).  
 
 
Missing data and imputations 
Missing data represent a persistent problem in epidemiology.  Missing data may arise from a 
patients’ refusal or non-eligibility to participate in the study, or from single values missing in the 
data set. The data registries used in this thesis have evolved during the past decades and new data 
has been included in the database. Missing laboratory values may be due to failure in the 
procedure producing the value or may simply not be included in the database during the first 
years of registration. Consequently, although we searched the patients’ records for missing 
values, data may not be included in the medical records and thus not available for retrospective 
data collection. 
One approach to deal with missing values is to exclude all cases with missing values and to 
perform a complete case analysis (157). If the data are missing completely at random (MCAR) 
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the analysis remains unbiased. On the other hand, since whole data sets of each subject with 
missing values are excluded, statistical power may be lost. Data missing at random (MAR) is the 
more common and non-ignorable form of missing data and may constitute a major statistical 
concern. However, data MAR follows a recognizable pattern and missing values may be 
estimated from these patterns (158).  Different types of missing values are explained in Table 7. 
If data are not MAR or MCAR they are classified as missing not at random (MNAR) (157). By 
examining data sets it is not possible to distinguish between data MAR and data MNAR, but data 
MNAR may be processed as data MAR if additional variables that correlates to the missing data 
are included (157;159). Nonetheless, the statistical software for creating multiple imputations 
assumes that the data are MAR and even if the assumption of MAR is incorrect, the multiple 
imputation will provide improved estimates (159). 
Table 7. Types of missing data 
Term Explanation 
Missing completely at random Data are distributed across all observations and are independent of other data. 
Missing at random Data are distributed by identifiable patterns 
Missing not at random Data are not related to neither observed nor missing values 
 
The values used to replace missing data are generated by regression models taking all other 
variables in the data set into consideration. For example, blood pressure may be systematically 
related to age, gender and BMI. Consequently a missing value for blood pressure may be 
predicted from a combination of these values. The number of variables in the imputation model 
correlates to the accuracy of the imputed data (159). Accordingly, multiple imputations creating 
multiple data sets rather than a single one is preferred with 3-5 iterations of imputations 
recommended (160). If the proportion of missing data is high, a higher number of iterations are 
needed. To reduce the risk of systematic bias it is recommended to perform multiple imputations 
on variables with more than 10% missing data. On the other hand, imputation of data is not 
recommended if the proportion of missing data exceeds 60% (161).   
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Paper 1 – Screening and diagnostic considerations for new-onset diabetes after renal 
transplantation, receiver operating characteristic analysis 
NODAT was diagnosed by a 2hPG ≥11.1 mmol/l. Renal transplant recipients with an fPG ≥7.0 
mmol/l were excluded from the final analysis as these patients would not require an OGTT in 
clinical practice. We used ROC analysis to evaluate the diagnostic accuracy of fPG and HbA1c 
and to define the optimal cut-off values to predict NODAT. Our choice of cut-off value for fPG 
and HbA1c to prompt a subsequent OGTT was based upon a clinical evaluation that a minimum 
of 80% of the recipients with undetected NODAT should be diagnosed from the screening 
algorithm.  
Paper 2 – Reduced incidence of new-onset diabetes after renal transplantation, logistic 
regression analysis 
Sample size was calculated based on an assumption of 50% reduction in the NODAT incidence 
found in the historical cohort of 1995-96 (28). More than 300 recipients were needed to secure a 
statistical power of 80% (α=0.05). Thus all patients transplanted during a period of two years 
were evaluated for inclusion. We used univariate and multivariate logistic regression to compare 
the binary outcome data of NODAT incidence (yes/no) of the new cohort of renal transplanted 
patients with a historical cohort of patients who received a renal transplant a decade earlier. 
Possible predictors of NODAT were selected a priori based on analysis of the historical cohort 
(28). The results were presented as Odds Ratios (ORs) with 95% confidence intervals (CIs).  
Paper 3 – Association of post-transplant glycemia with mortality, Kaplan Meyer and Cox 
regression analysis 
Kaplan-Meier plots and log-rank test were used to analyze cumulative survival for the various 
glucose categories. For the mortality assessment we used Cox proportional regression analysis 
with 2hPG as the time dependent variable. The analysis was adjusted for well established 
confounders in the multivariable analysis. We adjusted for a total of 14 confounders in the final 
models. Adjustments for ten events per confounding variable are generally accepted as a rule of 
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thumb (162-164). In our models for all-cause mortality a total of 282 events occurred, but the 
cause-specific analysis was based on fewer events (CVD 120, malignancy 65, infectious disease 
67, and other causes 17). Nonetheless, findings of a large study showed that acceptable results 
were achieved from multivariable regression analysis even with less than ten events per predictor 
variable (165). The results were presented as Hazard Ratios (HRs) with 95% CIs. Cox regression 
analysis assumes proportionality between the covariates. Model discrimination was assessed by 
Harrell’s concordance index (c-statistic). The relationship between the dependent and 
independent variables was assessed using multiple fractional polynomials (166), which allows for 
linear and non-linear relationships between a continuous independent variable and the outcome 
data. Multiple fractional polynomials present the relationship with the best fit for all the 
covariates included in the model.  
Since the aim of this study was to assess the relationship between hyperglycemia and mortality, 
we chose not to perform multiple imputations on glucose measurements obtained by the OGTT 
ten weeks post-transplant. Patients who were not able to perform the OGTT were not included in 
the study. The following confounding variables with missing data were imputed: hypertension 
(32%), smoking status (27%), total cholesterol (10%), height (3%), weight (3%), and CMV (1%). 
During the imputation process both complete and incomplete data sets were used as predictors 
and10 iterations were generated to compensate for the number of missing data, each containing a 
complete data set. Subsequently, each data set was analyzed and thereafter pooled to achieve a 
single variable estimate.  
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RESULTS 
Paper 1 - Screening and diagnostic considerations for new-onset 
diabetes after renal transplantation 
Screening for new-onset diabetes after renal transplantation 
Using a large cohort of renal transplant recipient who underwent an OGTT at10 weeks post-
transplant, we found that the majority of transplant patients who developed NODAT were 
identified by a 2hPG ≥11.1 mmol/l after an OGTT. Of the recipients with NODAT, 80% were 
identified from a 2hPG≥11.1 mmol/l, whereas only 50% whereas identified from an fPG≥7.0 
mmol/l. 
After excluding recipients who had an fPG < 7.0 mmol/l, we identified three two step screening 
algorithms, all reaching an 80% sensitivity level: 1) fPG ≥5.3 mmol/l, 2) HbA1c ≥5.8% and 3) 
fPG ≥5.0 and HbA1c ≥5.7 combined. The screening algorithms reduced the number of renal 
recipients needed to undergo an OGTT to 49%, 40% and 29%, respectively (Table 8).  
Table 8. Screening algorithms for NODAT based on fasting plasma glucose or HbA1c, using two hour 
plasma glucose as the “gold standard”. 
Cut-off value OGTT needed (%) Sensitivity (%) 
Positive 
likelihood ratio 
Negative 
likelihood ratio 
Fasting glucose 5.3 mmol/l 49% 81% 1.7 0.4 
HbA1c 5.8% 40% 83 % 2.2 0.3 
Fasting glucose 5.0 mmol/l 
AND HbA1c 5.7% 
29% 79% 2.9 0.3 
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Paper 2 - Reduced incidence of new-onset diabetes after renal 
transplantation 
In a comparative observational cohort 
study we compared data from a new 
cohort transplanted in 2004-2005 with a 
historical cohort transplanted in 1995-
96. We found that the incidences of 
NODAT and preDM ten weeks after 
renal transplantation were reduced from 
20% and 32% in the historical cohort to 
13% and 18% in the new cohort (both 
P<0.001). The incidence of NGT had 
increased from 48% in the historical 
cohort to 69% in the new cohort 
(P<0.001) (Figure 4).  The recipients in 
the new cohort were older (mean 47 [SD 
16] vs. 50 [15] years. P=0.038) and had a higher BMI (23.5 [3.8] vs. 24.5 [3.6] kg/m2, P=0.003) 
than the historical cohort. The majority of the study participants received prednisolone and CNIs 
as part of their standard immunosuppressive therapy. The CsA doses and trough levels were 
significantly lower in the new cohort compared to the historical cohort (216 [86] vs. 242 [60] 
µg/l, P<0.001) and more recipients used tacrolimus (21% vs. 2%, P<0.001). 
The odds of having NODAT were reduced by more than half in the new cohort compared to NC 
(OR 0.44 [95% CI 0.26-0.74]). The results were largely unchanged after multivariable 
adjustments for recipient age, prednisolone dose, early CMV infection and HLA-B27 (0.42 [0.23-
0.77]).  
Figure 4. Incidence of new-onset diabetes after renal 
transplantation  (NODAT), pre-diabetes (PreDM) 
and normal glucose tolerance (NGT) at ten weeks 
after transplantation in the historical (HC) and the 
new cohort (NC). 
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Paper 3 – Association of post-transplant glycaemia with mortality 
We followed a number of 1,471 renal transplant recipients transplanted between 1995 and 2006 
with no previous diagnosis of DM for a median of 6.7 (range 0.3-13.8) years. At ten weeks post-
transplant 242 (17%) had developed NODAT, 313 (22%) IGT, 217 (16%) IFG, and 638 (45%) 
NGT.  
Using ADA glucose categories as 
independent variables, patients with 
NODAT and IGT had significantly 
higher all cause mortality than 
recipients with NGT (reference 
category) (HR 1.54 [95% CI 1.09-2-17] 
and 1.39 [1.01-1.91]). In contrast, IFG 
was not associated with increased 
mortality risk (0.79 [0.52-1.23]). The 
results were largely unchanged using 
WHO diagnostic criteria for diabetes 
(Figure 5). 
The 2hPG, but not the fPG, measured ten weeks after transplantation was associated with all-
cause mortality. In the multiadjusted analysis, each 1 mmol/l increase in 2hPG was associated 
with HR 5% (95% CI 1%-9%) risk of dying.   
Subgroup analysis showed that NODAT was associated with 80% (10%-96%) increased risk of 
CV-death compared to NGT, whereas each mmol/l increase in fPG and 2hPG were associated 
with 19% (1%-39%) and 6% (1%-12%) increased risk of CV-death. Post-challenge 
hyperglycemia (2hPG ≥7.8 mmol/l) was associated with increased death from infectious disease 
(1.91 [1.09-3.33]). 
Figure 5. Multiadjusted HR (95% confidence 
intervals) for glucose categories measured ten weeks 
after renal transplantation.  
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DISCUSSION 
Recommendations for diagnosing new-onset diabetes after renal 
transplantation 
The preferred diagnostic test for new-onset diabetes after renal transplantation 
Our study supported the finding of a previous study that a 2hPG is superior to fPG for the 
identification of patients with NODAT in a renal transplant population (26). The use of fPG 
would have identified only half of the recipients with NODAT, whereas more than 80% of the 
recipients would have been identified from the 2hPG ≥11.1 mmol/l. The lack of a standardized of 
methods to diagnose NODAT, various time intervals between transplantation and diagnostic 
procedures, and different immunosuppressive regimens have contributed to the diversity of the 
NODAT incidence (167). A major strength of the studies discussed in this thesis is the large 
cohorts of consecutively included non-diabetic renal transplant recipients who underwent an 
OGTT with the same time interval between transplantation and diagnosis (70 [9] days). We have 
used 2hPG ≥11.1 mmol/l as the reference for diagnosing NODAT and our results cohere with 
other studies examining patients with an OGTT at various time intervals post-transplant (Table 
9). Accordingly, we have strengthened the evidence of early diagnosed NODAT the incidence 
among Caucasian transplant recipients. 
 
The optimal time to diagnose new-onset diabetes after renal transplantation 
The optimal time post-transplant to test for NODAT is unclear. In the immediate post-transplant 
period, the immunosuppressive therapy consists of high doses of immunosuppressive therapy 
which places the glucose metabolism under increased stress. Since most of the cases of NODAT 
develop within three months after transplantation, the testing period would seem reasonable at 
three to four months post-transplant (19). Furthermore, partial reversibility of NODAT in parallel 
with lower immunosuppressive doses is well acknowledged. In a recent study of 555 renal 
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transplant recipients, 18% of recipients developed NODAT within an average of 242 (SD 640) 
days and 31 out of the 102 NODAT cases resolved within three months post-transplant (168). 
This study however, defined NODAT as an fPG ≥7.8 mmol/l on at least two consecutive 
measurements or requirements of oral antidiabetic treatment and may thus have underestimated 
the true NODAT incidence. Another study showed that 16% of the recipients who develop 
NODAT within the first post-transplant year recovered to have NGT after 7 years, whereas some 
developed late NODAT beyond one year post-transplantation (32). Another study showed that 
five out of 12 recipients (42%) with NODAT at ten weeks post-transplant regressed to NGT 
(n=4) or IGT (n=1) after 6 years (69). On the other hand, a normal OGTT at day 5 post-transplant 
was associated with reduced risk of NODAT during the first post-transplant year in a prospective 
study of 359 renal transplant recipients (68). At ten weeks post-transplant, testing for diabetes 
might be too early and consequently, we might have overestimated the incidence of NODAT.  
Table 9. Overall incidences of New-onset diabetes after renal transplantation defined by an oral glucose 
tolerance test and at various time intervals between transplantation and diagnostic procedures 
 NODAT incidence (%) 
Immunosuppressive 
regimens 
 Months posttransplant 
Study 3 6 12 48 84  
Hagen et. al, 2003, Norway, n=63 (84) 19   22  Pred/CsA/Aza 
David-Neto et al. 2007, Brazil, n=84 (36) 12 8 8   Pred/Tac/MMF 
Hur et al, 2007, Korea, n=77 (32)   39  35 Pred/CsA/MMF 
Porrini et al., 2008, Spain, n=154 (74) 19  20   Pred/Tac/MMF 
Pred; prednisolone, CsA; cyclosporine, Tac; tacrolimus, A, Aza; azathioprine, MMF; mycophenolate 
mofetil. 
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The ideal time to perform the first post-transplant OGTT might be further postponed to 4-12 
months post-transplantation, concurrently with the time most patients would have reached a 
maintenance dosage for immunosuppressive medications and the risk of opportunistic viral 
infections would have been reduced. Furthermore, after 4 months the erythrocyte turnover would 
have normalized and thus HbA1c might better concur with the glucose concentration in serum 
(142). However, at our center ten weeks time post-transplant is a feasible approach because at 
this time the patients leave the hospital after being closely monitored during the early post-
transplant period. Performing an OGTT as early as ten weeks post-transplantation contributed to 
a more comprehensive patient inclusion and reduced the risk of selection bias in the study 
population.  
 
Paper 1 - Screening and diagnostic considerations for new-onset 
diabetes after renal transplantation 
Screening for new-onset diabetes after renal transplantation 
Our study shows that the HbA1c have 
comparable diagnostic accuracy with 
fPG in the early post-transplant period 
using a 2hPG ≥11.1 mmol/l as the 
reference. Although 2hPG is superior to 
fPG in the identification of NODAT, an 
OGTT may not be feasible in clinical 
practice. On the other hand, HbA1c may 
be useful in a two-step screening 
approach using a lower test-threshold to 
prompt a further diagnostic test for 
diabetes. In this sense, it would provide 
an additional tool for the identification 
Figure 6. Diagnostic accuracy of HbA1c explored by 
receiver operating characteristic analysis ten weeks 
after renal transplantation. 
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of patients at increased risk of CVD and mortality. We suggest that renal transplant recipients 
with an HbA1c ≥5.8% ten weeks post-transplant are referred to an OGTT for verification of 
NODAT. Alternatively, recipients with an fPG ≥5.3 mmol/l may be referred to an OGTT. By 
these two algorithms 80% of the NODAT patients would be identified and 40% and 50% of the 
population would have to undergo an OGTT. The combined criterion of fPG ≥ 5.0 mmol/l and 
HbA1c ≥5.7% would provide additional cost benefit and a comparable sensitivity, however, the 
screening algorithm may not be feasible to implement in a clinical setting. Accordingly, the usage 
of fPG and/or HbA1c as the primary screening tool for NODAT would require fewer patients to 
undergo an OGTT and thus provide a cost-benefit to the identification of NODAT.  
 
Choosing optimal cut-points 
The choice of a cut-off value should be based on expert opinions in addition to the ROC analysis. 
In this decision, an evaluation on how important it is to minimize the occurrence of false negative 
or positive results should be included. Clinical conditions such as the prevalence and gravity of a 
disease in addition to the purpose of the test should be taken into account. Increasing the 
sensitivity of a test will always be at the expense of decreased specificity and vice versa. 
Armstrong et al. examined 188 renal transplant recipients with an OGTT on average 6.6 years 
post-transplant and suggested that fPG of 5.6 mmol/l was the optimal threshold for referral to a 
subsequent diagnostic OGTT, predicting a diabetic 2hPG ≥11.1 mmol/l with a sensitivity of 64%. 
In this study, an fPG of 5.3 mmol/l and 5.0 mmol/l showed a sensitivity of 77% and 86%, which 
is comparable with the findings in our study (81% and 91%, respectively) (26). However, given 
the serious consequences of NODAT, we would argue for a lower cutoff to incite a subsequent 
diagnostic OGTT for the verification of the diagnosis. 
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Pre-transplant risk assessment of new-onset diabetes after renal transplantation 
Some studies have reported abnormalities in the glucose metabolism before renal transplantation 
as predictors for the development of NODAT (64;65;116). In addition, a recent study showed that 
a simple pre-transplant risk score calculated from pre-transplant age, family history of type 2 
diabetes, BMI, fPG, TG, use of goat medicine and predicted use of corticosteroids post-transplant 
predicted the onset of diabetes within the first year after transplantation (169). This study, 
however, used an fPG <7.0 mmol/l and HbA1c <6.5% for the exclusion of the diagnosis of 
diabetes mellitus pre-transplant and might have underestimated the true prevalence of diabetes  
mellitus before transplantation. In a study of 889 non-diabetic renal transplant candidates on the 
waiting list, pre-transplant levels of fPG ≥7.0 mmol/l predicted a 2hPG ≥11.1 mmol/l in only 
22% of the cases. This study also showed that the diagnostic accuracy for HbA1c in detecting a 
2hPG ≥11.1mmol/l was poor, predicting a 2hPG ≥11.1 mmol/l in only 58% of cases (50). One 
small study found that pre-transplant glucose abnormalities identified by an OGTT were highly 
specific (96%), but had low sensitivity (23%) in predicting NODAT at six months after 
transplantation, whereas random blood glucose was associated with a higher diagnostic accuracy 
than fPG or 2hPG (170). Also, only half of the renal transplant recipients with NODAT 12 
months post-transplant had IGT before transplantation in a recent prospective study of 97 non-
diabetic uremic patients on the waiting list (56). Furthermore, one study demonstrated that home 
glucometer monitoring improved the diagnosis of NODAT compared to an fPG in clinical visits 
(171). Nonetheless, since a major concern of transplant clinicians is the prevention of long-term 
complications, early identification of recipients with increased risk of premature death is crucial 
for the implementation of risk reducing strategies. Accordingly, the identification of renal 
transplant recipients at risk of developing NODAT should be addressed both before and after 
renal transplantation. 
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Validation of HbA1c ≥6.5% for the diagnosis of new-onset diabetes after renal transplantation. 
A post hoc analysis of 976 recipients with HbA1c available (including patients with fPG≥7.0 
mmol/l) showed that 76 patients had an HbA1c ≥6.5%. and 94 recipients had NODAT defined by 
either an fPG ≥7.0 mmol/l or a 2hPG ≥11.1 mmol/l. The AUC for HbA1c for identifying 
NODAT by either a 2hPG ≥11.1 mmol/l or an fPG ≥7.0 mmol/l was 0.828 (95% CI 0.785-0.872). 
The ROC curve is presented in Figure 6. The sensitivity, specificity, predictive values and 
likelihood ratios for HbA1c ≥6.5% are presented in Table 10. A sensitivity of 42% would leave 
55 out of 94 with undetected NODAT. A positive diagnostic likelihood ratio of 9.9 indicates that 
HbA1c is strongly associated with the presence of NODAT. On the other hand, although an 
HbA1c < 6.5% indicated the absence of NODAT, a negative likelihood ratio of 0.611 is not small 
enough to rule out the disease with confidence. Nevertheless, the majority of the recipients with 
NODAT had an HbA1c < 6.5% and would remain undetected by this diagnostic approach and 
consequently, we argue that a diagnostic threshold for HbA1c ≥6.5% might be too high in a renal 
transplant population early post-transplant.  
Table 10. Validation of the diagnostic cut-point of HbA1c≥6.5% for the 
diagnosis of new-onset diabetes mellitus in a renal transplant population 
ten weeks after renal transplantation. 
 
Renal transplant recipients 
(n=976) 
Sensitivity 0.415 
Specificity 0.958 
Positive predictive value 0.513 
Negative predictive value 0.939 
Positive likelihood ratio 9.890 
Negative likelihood ratio 0.611 
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Our results showed that as early as ten weeks post-transplant, HbA1c correlated with a 2hPG 
≥11.1 mmol/l in 83% of the NODAT cases. In a study of patients with ESRD, HbA1c correlated 
poorly with 2hPG ≥11.1 mmol/l in patients with ESRD (50). These studies add practical clinical 
evidence to the identification of patients with undetected diabetes before and early after renal 
transplantation and suggest that the diagnostic value of HbA1c may differ between ESRD and 
kidney transplant recipients. Different mechanisms may be involved in the development of 
diabetes before and after transplantation and a distinction should be made between these two 
groups of patients in the interpretation of HbA1c values.  
 
Paper 2 - Reduced incidence of new-onset diabetes after renal 
transplantation 
This thesis has shown that, although the NODAT incidence has been reduced in a cohort of 
recipients transplanted in 1995-96 compared to a cohort of patients transplanted in 2004-05, 
NODAT is a common complication after renal transplantation. The NODAT incidence was lower 
in the new cohort than the historical cohort in spite of a higher average age and BMI, both known 
to increase the risk of NODAT. Accordingly, the reduced NODAT incidence might be explained 
by non-traditional risk factors such as a change in the immunosuppressive medication from 
azathioprine to MMF and consequently lower rejection rates and steroid doses. Increasing 
recipient age was associated with lower rates of rejections in a large study of more than 100,000 
renal transplant recipients registered in the United Network for Organ Sharing database (172). 
Furthermore, lower CsA doses and a switch from deferred to pre-emptive treatment of CMV 
infection might have contributed to the lower NODAT incidence.  
Our findings cohere with other studies of early incident NODAT as diagnosed by a 2hPG ≥11.1 
mmol/l after an OGTT including different immunosuppressive regimens (Table 9). Although a 
2hPG ≥11.1 mmol/l may identify a higher proportion of renal transplant patients with NODAT 
than fPG ≥7.0 mmol/l, the findings in our study also concur with studies not using the 
recommended diagnostic criteria for NODAT. A meta-analysis of 16 studies including more than 
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Figure 7.  Serum insulin concentrations during 
hyperglycemic glucose clamp procedures before 
(filled squares) and after (open circles) CsA 
treatment. Reprinted with kind permission of the 
authors and Nephrology, Dialysis and 
Transplantation (176). 
 
3,000 patients receiving a calcineurin based immunosuppressive regimen showed that 13% of the 
recipients developed NODAT as defined by “insulin dependence” (i.e. treatment with insulin in 
previous non-diabetic subjects) during the first year after transplantation (102). A U.S. population 
based study showed a cumulative incidence of NODAT defined by using data from Medicare 
claims increasing from 9% at 3 months after transplantation, to 16% at 12 months and 24% at 36 
months post-transplant (19).   
 
Type of immunosuppressive regimens 
Corticosteroids are the most consistently reported determinant of glucose intolerance in a renal 
transplant population (21;94;173).  Considering that a 2hPG after and OGTT identifies more 
patients with NODAT, a link between 2hPG and corticosteroid might explain this relationship. 
When the 2hPG 2-hr serum glucose was considered a continuous variable, multivariate linear 
regression analysis showed that the association between prednisolone dose and glucose 
intolerance was strengthened (28). Each 1 mg reduction of prednisolone was further associated 
with a 0.12 mmol/l decline in 2hPG during the first year after renal transplantation (173). 
The choice of CNI may also contribute to the 
diversity of NODAT incidence. In a large 
prospective study a total of 682 de novo renal 
transplant recipients were randomized to 
either tacrolimus or CsA in addition to 
corticosteroids, mycophenolate mofetil and 
basiliximab. After six months, the incidence 
of the composite endpoint of IFG or NODAT 
was higher in the tacrolimus group than the 
CsA group (34% vs. 26%, P=0.046) (35). 
Notably, one study found that after a 
successful renal transplantation, a CsA based 
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immunosuppressive regimen maintained normal insulin-secreting ability in high risk patients, 
whereas a tacrolimus based regimen did not (65). On the other hand,  a study of non-diabetic 
patients in hemodialysis showed that short-term treatment with CsA decreased the second phase 
insulin secretion, whereas no significant change was observed in the average first phase of insulin 
secretion (Figure 7) (174). In our study the majority of subjects used a CsA based 
immunosuppressive regimen. Interestingly, we found a lower NODAT incidence in the new 
cohort than the historical cohort in spite of a higher proportion of recipients treated with 
tacrolimus (65 [21%] versus 4 [2%], P<0.001). However, the overall number of renal transplant 
recipients receiving tacrolimus was small, and the results should be interpreted with care.  
Recent studies indicate that the mTOR sirolimus is highly diabetogenic (99;105). One study of 
395 renal transplant recipients showed that the recipients on sirolimus had a 3.5 times increased 
risk of developing NODAT compared to recipients with no sirolimus (HR 3.5 [95% CI 1.5-8.3]) 
(105). In a small study of 41 renal transplant recipients, both insulin release and insulin 
sensitivity were impaired after conversion to sirolimus and the increased insulin sensitivity 
correlated with the change of serum triglycerides (101). Whether the mTOR, everolimus, has a 
comparable effect on the glucose metabolism is not known. Impaired glucose homeostasis in 
renal transplant recipients receiving induction therapy with basiliximab was observed in a single 
center retrospective study of 264 patients (108). This finding has, however, not been verified in 
other studies. Furthermore, alemtuzumab induction therapy was associated with a decreased risk 
of NODAT, as reported in the Organ Procurement Transplant Network/United Network of Organ 
Sharing database (30).  Our study participants were predominantly treated with a CsA based 
regiment, and induction therapy was not included in the immunosuppressive protocols for either 
the historical cohort or the new cohort. 
 
Steroid free protocols, withdrawal or tapering 
Given the close relationship between corticosteroids doses and impaired glucose metabolism, a 
reduction in the incidence of NODAT is consistent with the introduction of newer and more 
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potent immunosuppressive medication and subsequent reduced rejection rates and lower steroid 
doses. Steroid free protocols would potentially reduce the risk of NODAT without an increased 
risk of acute rejections, and lower rates of NODAT have been reported in renal transplant 
recipients on prednisolone-free maintenance immunosuppression therapy (91). Furthermore, de 
novo use of antihyperglycemic medication was significantly lower in a steroid free group 
compared to patients receiving standard steroid therapy in a randomized multicenter study (175). 
However, conflicting evidence exists on the occurrence of acute rejections rates and long-term 
outcomes after early steroid withdrawal or tapering. Some studies have suggested that avoiding 
steroid therapy increased the risk of acute allograft rejection without adversely affecting patients 
and graft survival (96;175-177). By contrast, a meta-analysis of immunosuppression withdrawal 
trials showed an increased proportion of patients with acute rejection (mean difference 0.14 
[95%c CI 0.10-0.17]) and an increased risk of graft failure (RR 1.38 [1.08-1.67]) after steroid 
withdrawal (97). A large US data register showed that renal transplant recipients discharged 
without steroids who were restarted on corticosteroids after 6-12 months had a 20% (95% CI 
11%-32%) increased risk of graft failure (93). Nevertheless, withdrawal of 5 mg prednisolone 
may not influence insulin sensitivity significantly (95). 
 
Dosage and blood levels of immunosuppressive drugs 
The diabetogenic risk associated with prednisolone is probably dose related (28;173). In keeping 
with another study, we found a positive continuous relationship between steroid dosage and 
NODAT (28). In our study, each 1 mg increased prednisolone dose was associated with 11% 
increased multiadjusted odds of developing NODAT. Nevertheless, tapering off prednisolone has 
beneficial effects on insulin action and glucose tolerance after renal transplantation, but a 
reduction below 5 mg/day may not influence insulin sensitivity significantly (95;173). 
Targeting CNI concentrations levels in order to minimize risk factors for CVD or nephrotoxicity, 
while maintaining adequate immunosuppressive effect such as to avoid acute rejection, is of 
clinical interest. Studies have suggested that C2 levels of CsA are superior to the C0 levels in 
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predicting early post-transplant CsA exposure and acute rejection after renal transplantation 
(178;179).  On the other hand, a recent study of 225 renal transplant recipients reported that both 
C2 and C0 were useful to predict CsA side effects (180). In our study the dosages of CsA were 
adjusted according to C0 levels in the historical cohort and according to C2 levels in the new 
cohort. However, for comparison, mean C0 levels were reported in the study. Both the C0 levels 
and the CsA doses were significantly lower in the new cohort compared to the historical cohort 
(216 vs. 242 µg/l and 312 vs. 342 mg/day, both P <0.001). Given that the impact of CNI on 
glucose intolerance may be dose related, a lower CsA dose might have contributed to the reduced 
NODAT incidence observed in the new cohort (181). A CNI minimizing strategy may be 
advantageous in terms of renal function by reduced rejection rates as well as for adverse effects 
such as NODAT in the short-term. However, although the CNI minimization strategies may 
reduce short-term outcome after renal transplantation, recent studies have reported that the most 
common cause of late graft failure is immunologic, indicating that inappropriate low exposure to 
immunosuppressive therapy may result in chronic allograft rejection (182). 
 
Cytomegalovirus infection: in or out? 
A tendency towards lower CMV infection was seen in the new cohort compared to the historical 
cohort (54% vs. 63%, P=0.071). Although  both the CMV pp65 antigen positive cell detection 
and the CMV DNA PCR detection are able to detect CMV in blood before the onset of  CMV 
disease, the usage of a PCR technique for the detection of CMV DNA is reported to be more 
sensitive for the prediction of future CMV disease (144). Thus, the reduced incidence of CMV 
infection in the new cohort compared to the historical cohort might have been underestimated in 
this study. However, the reduced incidence of NODAT during the past few decades is more likely 
to be explained by a change from deferred to pre-emptive treatment of CMV infection. In the 
historical cohort, patients were treated with ganciclovir when they experienced clinical symptoms 
of CMV infection, whereas in the new cohort, patients with asymptomatic CMV infection as 
defined by a positive screening test for CMV were treated orally with valganciclovir.  
Accordingly, this change in CMV treatment might have contributed to a lower peak and duration 
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of viral load in addition to a tendency towards lower CMV infection rate. Thus, given the link 
between CMV infection and the development of NODAT, the change from deferred to pre-
emptive CMV treatment might have contributed to the reduced incidence seen in the new cohort. 
 
Paper 3 - Association of post-transplant glycemia with mortality 
Our data indicate that a 2hPG is superior to and independent of fPG in predicting long-term 
mortality outcome. In our study each 1 mmol/l increased 2hPG was associated with 5% increased 
risk of death from any cause and a 6% increased risk of death from CV disease. Similar risk-
estimates (6% increased risk of all-cause mortality per 1 mmol/l increment in 2hPG) for all cause 
mortality were recently presented in a study of 505 type 2 diabetic patients (183). In this study 
self-monitored postprandial blood glucose and HbA1c independently predicted CV events and 
all-cause mortality whereas fPG did not. These risk-estimates support the results of our study and 
extend the validity to a non-transplant population. Large epidemiological studies have shown that 
renal transplant recipients with NODAT diagnosed by Medicare claims or by the need of glucose 
lowering treatment, have a two-fold increased all cause mortality risk compared to recipients 
without NODAT (18;19). One study investigated the mortality risk in a renal transplant 
population by comparing both patients with pre-existing diabetes before transplantation and 
patients with NODAT with non-diabetic patients (18). A survival plot starting at the time of 
NODAT diagnosis was superimposable with the survival plots for recipients with pre-existing 
diabetes and it was significantly different from the survival of patients without diabetes (18). This 
finding indicates that the development of NODAT may be associated with an accelerated 
progression of diabetes related complications affecting patient survival. The results of our study 
partly cohere with the findings of these two studies and extend the validity of the results to 
NODAT defined by a 2hPG ≥11.1 mmol/l. 
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Causes of death after renal transplantation 
The main cause of death among renal transplant patients with NODAT is CVD, accounting for 
nearly half the deaths after renal transplantation (18;119;184). The prevalence of CVD among 
recipients with pre-existing diabetes and NODAT is reported to be higher than in recipients 
without diabetes which might explain the higher prevalence of CV deaths among recipients with 
NODAT compared to NGT (119). However, a significant reduction in the CV death rate has been 
demonstrated from the early 1980’s to the modern times (adjusted RR 0.61 [95% CI 0.36-0.96]), 
suggesting improvements in CV risk management and patients outcome after renal 
transplantation (8). However, although the number of CV-deaths was reduced, the proportion of 
deaths attributable to CV disease has remained unchanged during the last decades, whereas the 
reduction of death rates may have been caused by a decline in death by infectious disease (8). 
The proportion of CV deaths (42%) found in our study cohere with these other studies, whereas 
the proportion of deaths from malignant disease and infectious disease differed (8;184). Our 
results included only 5% deaths from unknown causes which indicate a higher proportion of 
death from any of the other known causes. 
 
Impact of categorization of continuous glucose measurement 
Assessments of glucose consist of values measured on a continuous scale and categorizing the 
glucose measurements into glucose categories may contribute to loss of variation within each 
category. For instance, the mortality risk of a patient with a 2hPG of 7.7 mmol/l may not be 
significantly different from a patient with a 2hPG of 7.9 mol/l although by categorization, they 
represent different categories (NGT and IGT, respectively). 
Although the relationship between continuously measured fPG and all-cause mortality was not 
statistically significant in our study, a trend of reduced patient survival was shown. In addition, a 
J-shaped relationship between fPG and cause-specific death has been reported in a general 
population (127).  A possible J-shaped relationship between the dependent and independent 
variable in a proportional Cox regression analysis might contribute to an underestimation of the 
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risk associated with fPG by a false assumption of proportionality. In our study, however, we were 
unable to confirm a non-linear relationship using multivariable fractional polynomials and no 
non-linear models of either fPG or 2hPG outperformed the linear model in our sets of data. 
 
 The risk of cardiovascular disease with transient diabetes after renal transplantation 
We assessed the association between OGTT derived blood glucose levels measured ten weeks 
after renal transplantation and long-term mortality outcome without a repeated diagnostic test. By 
three months post-transplant the immunosuppressive treatment is lowered to a maintenance levels 
and consequently the impact of immunosuppressive drugs on glycemia may have been reduced. 
As is shown in Table 9, the incidence of NODAT is lower beyond the first three months post-
transplant and consequently, the CV risk of patients with transient NODAT might be reduced in 
this subgroup of patients. Cosio et al. found that the incidence of CV events in recipients with 
persistent NODAT, NODAT that resolved within one month and euglycemia was 23%, 10% and 
11%, respectively (31). A post hoc analysis of 23 patients showed that a major cardiac event 
occurred more frequently in patients with persistent NODAT (n=11) compared to recipients with 
transient NODAT (n=12) (none vs. 36%, P=0.037) (119). These findings underline the 
importance of early identification and repeated assessment of glucose abnormalities to help 
attenuate or regress the development of NODAT and to prevent CV events.  
 
Is pre-diabetes after renal transplantation a predictor for mortality? 
In the general population, it is well established that persons with preDM, either IFG or IGT are 
associated with increased mortality risk (123;131;185). However, no previous studies have 
assessed the impact of preDM on long-term mortality outcome in a renal transplant population. 
Using fPG 5.0-5.5 mmol/l as the reference, one study of renal transplant recipients reported a 
two-fold increased risk of CV events at five years of patients with fPG 6.1-6.9 mmol/l (IFG by 
WHO), but not for patients with fPG levels between 5.6-6.0 mmol/l (IFG by ADA) (31). We 
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found no association between IFG and mortality using either ADA or WHO criteria for IFG.  The 
Emerging Risk Factors Collaboration (ERFC) recently demonstrated an association between 
increasing fasting glucose levels ≥ 5.6mmol/l and non-vascular, non-malignant mortality in a 
general population (127). In this study, post-challenge hyperglycemia, was neither addressed nor 
discussed as a possible limitation. Individuals with IFG might also have IGT, and thus, the 
ERFC-study did not address the effect of isolated IFG on non-vascular, non-malignant mortality. 
In our study, death from infectious disease accounted for the majority (69%) of non-vascular, 
non-malignant deaths. Furthermore, no association was found between fPG and malignant or 
infectious death. Post-challenge glucose ≥ 140mg/dl (7.8mmol/l) was associated with a 50% 
increased risk of infectious death. Nonetheless, our study is the first to indicate both that IGT is 
associated with increased risk of death from any cause and that post-challenge hyperglycemia 
correlates to increased risk of death from infectious diseases after renal transplantation. These 
finding, however, require verification from other populations. 
 
Isolated non-diabetic hyperglycemia: a predictor for mortality after renal transplantation? 
The isolated clinical contribution of post-transplant hyperglycemia to all-cause and CV mortality 
is unknown. Hyperglycemia is associated with other risk factors for all-cause mortality such as 
components of the metabolic syndrome. Consequently measurements of hyperglycemia may be a 
biomarker of increased mortality risk of causes other than abnormal glucose metabolism. 
Assessments of the impact of post-transplant hyperglycemia on long-term outcome are limited by 
variations of immunosuppressive therapy, relatively short-term follow-up, and the multifactorial 
risk management of the high risk population of renal transplant recipients. To clarify the 
contribution of hyperglycemia on patient survival, prospective studies addressing the impact of 
glucose lowering therapy on patient outcome are needed. One recent study of the general 
population aimed to assess the impact of post-prandial glucose lowering treatment with 
nateglinide in addition to lifestyle modification on incident diabetes or CV events (186). In this 
study, persons with IGT treated with nateglinide over a five year period did not show reduced 
incidence of diabetes or the composite cardiovascular endpoints. Furthermore, early intensive 
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multifactorial management of 3,057 patients with screen detected type 2 diabetes did not show a 
significant reduction in the five year incidence of CV events and death in the general population 
(187). In this study, the lack of differences between the intervention groups and the control group 
may be attributed to the quality of care delivered to both groups as the CV-risk factors were 
assessed, indicating that the screening process itself may be beneficial for patients unaware of the 
increased risk of morbidity and mortality. 
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LIMITATIONS 
In this thesis, less than 10% of the participants were unable to perform an OGTT and since the 
non-eligible patients were older and more likely to receive a kidney from a deceased donor, they 
might have contributed to a sample selection bias. On the other hand, since the patients not 
included in these studies were older, they might have had a higher risk of developing NODAT 
and consequently the NODAT incidence may have been underestimated.  
The participants in these studies were almost exclusively Caucasians and hepatitis C negative. 
Consequently, the results reported may neither apply to populations of other ethnicities nor to 
populations with a higher prevalence of hepatitis C. On the other hand, comparable results on 
NODAT incidence and evidence about the association between NODAT and patient survival 
have been reported in studies including multiple races and ethnicities (18;19). Furthermore, 
hepatitis C infection can be excluded as a potentially confounding variable in the interpretation of 
our results.  
Although a higher proportion of the recipients used tacrolimus in the new cohort than in the 
historical cohort, the majority of patients were maintained on a CsA based immunosuppressive 
regimen. Many transplant centers are currently using tacrolimus as the immunosuppressive drug 
of choice. Furthermore, less than 5% used a non CNI based immunosuppressive regimen (data 
not shown). The results of our study are thus constricted to a Norwegian renal transplant 
population using CsA and may not be valid in populations using other immunosuppressive 
therapy.  
Finally, we used a 2hPG ≥11.1 mmol/l as the “gold standard” for diagnosing NODAT. However, 
since different diagnostic criteria for diabetes (fPG, 2hPG and HbA1c) identify patients with 
different glucose metabolism, subgroups of patients may be diagnosed by an fPG ≥7.0 mmol/l 
alone or an HbA1c ≥6.5% alone. Consequently, by defining a 2hPG after an OGTT as the 
reference for diagnosing NODAT, some patients with NODAT may remain undetected.  
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CONCLUSIONS 
Our findings support the continued usage of a 2hPG ≥11.1 mmol/l as the more sensitive test for 
the identification of Norwegian subjects with unknown NODAT. Based on our results, we 
suggest that two screening algorithms may be feasible in a renal transplant population ten weeks 
post-transplant. An HbA1c ≥5.8% or an fPG ≥5.3 mmol/l may both be used as a primary 
screening test to select patients to a subsequent OGTT. By these screening algorithms 80% of the 
NODAT cases would have been identified and 40% and 50% of the renal transplant population 
would require an OGTT for the verification of NODAT. 
We have demonstrated that the incidence of NODAT among Norwegian renal transplant 
recipients in the early post-transplant period has declined during the last decade. Possible 
explanations for this improvement are more effective immunosuppressive therapy resulting in a 
lower frequency of acute rejection and consequently lower steroid doses and a change in the 
treatment strategy of CMV infection. 
We have also shown that early measured glycemia among Norwegian renal transplant recipients 
predicted long-term survival after renal transplantation and that postprandial hyperglycemia as 
expressed by 2hPG may be superior to fPG in predicting long-term overall mortality and CV 
mortality. Furthermore, we have demonstrated that the prediabetic glucose category; IGT, but not 
IFG, is associated with reduced long-term patient survival after renal transplantation. 
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IMPLICATIONS AND FUTURE PERSPECTIVES 
The prospective studies in this thesis included a large cohort of renal transplant recipients and 
may be said to have broadened the level of current understanding surrounding the association 
between early post-transplant hyperglycemia and patient mortality. The studies further support 
the continued usage of an OGTT for both diagnosing NODAT and predicting long-term mortality 
after renal transplantation. We have presented updated incidence figures of early NODAT in line 
with the recommendations for diagnosing diabetes. However, the incidence of NODAT will 
probably increase in line with the growing number of obese and older renal transplant recipients 
(188).  
 
The optimal test and time for diagnosing of new-onset diabetes after renal 
transplantation 
By performing a routine OGTT ten weeks after renal transplantation we have verified the 
superior diagnostic sensitivity of an OGTT. Most patients with NODAT have an elevated 2hPG 
after an OGTT, whereas fPG is often within the normal range. More than half the NODAT cases 
were identified from a 2hPG ≥11.1 mmol/l alone whereas 17% were identified from an fPG ≥7.0 
mmol/l and 32% fulfilled both the criteria. We argue therefore against the current guidelines 
which suggest that fPG should be the preferred diagnostic test. Nonetheless, performing an 
OGTT is time consuming and may be difficult to implement as a routine procedure in clinical 
practice. An alternate screening algorithm may therefore help clinicians to select a subgroup of 
patients in need of an OGTT for the verification of NODAT. 
In the general population, new diagnostic criteria suggest that three diagnostic tests are valid for 
the diagnosis of DM: fPG, 2hPG or HbA1c (37). Whether any single diagnostic test should be 
preferred in a renal transplantation population remains, however, unclear. Although the usage of 
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HbA1c as a diagnostic test may be welcomed in the general population, the usage of HbA1c in 
the screening and diagnosis of early NODAT has several limitations.  
The identification of the optimal time to test for NODAT needs further investigation. Whether a 
pre-transplant OGTT should guide the choice of immunosuppressive drug regimen is unclear. 
The rationale for most clinicians in selecting an optimal immunosuppressive therapy is to prevent 
acute rejection, whereas the predominant cause of graft loss is death with a functioning graft 
(184). Although pre-transplant testing for NODAT is reported to have low sensitivity for 
detecting post-transplant hyperglycemia, early identification of both pre-transplant 
hyperglycemia and NODAT is necessary in order to maintain vigilance regards risk reducing 
strategies after renal transplantation. To prevent NODAT risk assessment should be performed 
while patients are still on the waiting list.  Future studies should therefore focus on pre-transplant 
examination of the glucose metabolism in order to tailor immunosuppressive therapy such that it 
further reduces the risk of NODAT. In patients with increased risk of NODAT, lower doses of 
prednisolone or tacrolimus should be considered after surgery.  
 
Immunosuppressive therapy: impact on incident diabetes and long-term post-
transplant complications 
Newer immunosuppressive drugs may have contributed to the lower NODAT incidence during 
the last decade, possibly by mechanisms such as lower rejection rates and steroid doses. Current 
trends in immunosuppression focus on the development of novel agents, and further investigation 
will hopefully show whether new immunosuppressive drugs will contribute to a further reduction 
of NODAT incidence. The CNIs have been largely responsible for the low rates of rejections and 
thus improved short-time outcomes; however they have had little impact on long-term outcome 
after renal transplantation. Although CNI minimizing strategies may benefit renal transplant 
patients short-term, recent studies have shown that the most common cause of late allograft 
failure is immunologic (181;182). Thus, low exposure to immunosuppression in the long-term 
may result in recurrent disease or chronic alloimmune rejection. The nephrotoxicity and the 
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unfavorable metabolic side effects associated with current immunosuppressive therapy may be 
the predominant obstacle in securing improvements in long-term allograft outcomes. Further 
progress may depend upon new immunosuppressive agents with novel mechanisms of action and 
a minimum of toxic adverse effects.  Agents, targeting humoral immune system have shown 
improved metabolic risk profile although the acute rejection rates have been higher than for CNIs 
(189;190).   In parallel with the development of newer immunologic agents with minimal 
nephrotoxic adverse effects and impact on the recipients’ CV risk profile; we must continue to 
monitor risk factors for post-transplant morbidity and mortality.  
 
The role of isolated post-transplantation hyperglycemia in long-term 
morbidity and mortality 
Although a 2hPG after an OGTT may help select a sub-population with increased risk of 
premature death after renal transplantation, the specific contribution of post-transplant 
hyperglycemia is unclear. Epidemiological studies of the general population suggest that 
postprandial hyperglycemia positively affect the development of CVD, but randomized 
prospective studies targeting postprandial hyperglycemia have failed to provide evidence of 
reduced hard CV end points (191). Thus, post-prandial hyperglycemia may represent a marker 
rather than a risk factor of long-term complications.  Future randomized studies addressing the 
impact of glucose lowering treatment on long-term mortality outcome should investigate in a 
renal transplant population whether glucose lowering treatment reduces the risk of death. Also, in 
the context of limited organs there is a tendency of increased acceptance of donors which 
previously would have been considered unsuitable which may affect patient outcome after renal 
transplantation (192).  
Furthermore, the associations between NODAT and microvascular complications among renal 
transplant recipients are unknown. The evidence linking NODAT to microvascular complications 
is limited and the recommendations for screening and management of microvascular 
complications are in line with the recommendations of the non-transplant population. 
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Considering that NODAT may have accelerated progression of diabetes related complication, 
microvascular complications are likely to be prevalent in transplant population. In parallel with 
the implementation of risk reducing strategies in renal transplant populations, future studies 
should address the impact of NODAT on microvascular complications. 
 
Management of new-onset diabetes after renal transplantation  
Intensified lifestyle modifications should be encouraged to prevent and reduce CV risk after renal 
transplantation. Active lifestyle intervention has been reported to improve 2hPG in patients with 
IGT and NODAT and a regression of IGT to NGT in a renal transplant population followed for 
six months (74).  
There is a paucity of data concerning the usage of hypoglycemic agents after renal transplantation 
with guidelines predominantly derived from data of non-transplant populations. However, in a 
renal transplant population, the choice of hypoglycemic agents may not comply with the 
guidelines for treating type 2 diabetes. First, immunosuppressive drugs are associated with 
serious drug-interactions. Second, many renal transplant recipient have reduced GFR which may 
influence the choice of hypoglycemic drug. Metformin is established as the first line agent for 
type 2 diabetes. However, though it has been suggested that metformin is safe down to a 
minimum estimated GFR of 30 ml/min (193), clinicians are reluctant to prescribe metformin due 
to renal insufficiency. Third, renal transplant recipients often have advanced atherosclerosis and 
the choice of hypoglycemic treatment should aim to improve rather than increase their risk of 
progressive CVD. Accordingly, the drug of choice in a renal transplant population may include 
short-acting insulin secretagogues and possibly metformin in the context of an adequate kidney 
function (i.e. GFR above 50 ml/min). In any case, insulin should be administered in cases of 
persistent hyperglycemia. Future studies are needed in order to assess the efficacy and safety of 
hypoglycemic agents for the treatment of NODAT. 
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Abstract
Aims/objective We aimed to assess the long-term effects of
post-transplant glycaemia on long-term survival after renal
transplantation.
Methods Study participants were 1,410 consecutive trans-
plant recipients without known diabetes who underwent an
OGTT 10 weeks post-transplant and were observed for a
median of 6.7 years (range 0.3–13.8 years). The HRs adjusted
for age, sex, traditional risk factors and transplant-related risk
factors were estimated.
Results Each 1mmol/l increase in fasting plasma glucose (fPG)
or 2 h plasma glucose (2hPG) was associatedwith 11% (95%CI
−1%, 24%) and 5% (1%, 9%) increments in all-cause mortality
risk and 19% (1%, 39%) and 6% (1%, 12%) increments in
cardiovascular (CV) mortality risk, respectively. Including both
fPG and 2hPG in the multi-adjusted model the HR for 2hPG
remained unchanged, while the HR for fPG was attenuated
(1.05 [1.00, 1.11] and 0.97 [0.84, 1.14]). Compared with
recipients with normal glucose tolerance, patients with post-
transplant diabetes mellitus had higher all-cause and CV
mortality (1.54 [1.09, 2.17] and 1.80 [1.10, 2.96]), while patients
with impaired glucose tolerance (IGT) had higher all-cause, but
not CV mortality (1.39 [1.01, 1.91] and 1.04 [0.62, 1.74]).
Conversely, impaired fasting glucose was not associated with
increased all-cause or CV mortality (0.79 [0.52, 1.23] and 0.76
[0.39, 1.49]). Post-challenge hyperglycaemia predicted death
from any cause and infectious disease in the multivariable
analyses (1.49 [1.15, 1.95] and 1.91 [1.09, 3.33]).
Conclusions/interpretation For predicting all-cause and CV
mortality, 2hPG is superior to fPG after renal transplanta-
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tion. Also, early post-transplant diabetes, IGT and post-
challenge hyperglycaemia were significant predictors of
death. Future studies should determine whether an OGTT
helps identify renal transplant recipients at increased risk of
premature death.
Keywords Mortality after renal transplantation . New-onset
post-transplant diabetes mellitus . Oral glucose tolerance
test . Post-transplant complications
Abbreviations
2hPG 2 h plasma glucose after an OGTT
CV Cardiovascular
CMV Cytomegalovirus
fPG Plasma glucose after an overnight fast
IFG Impaired fasting glucose
IGT Impaired glucose tolerance
NGT Normal glucose tolerance
PTDM Post-transplant diabetes mellitus
Introduction
Renal transplant recipients have an increased risk of
premature death, with cardiovascular disease (CVD),
malignancy and infectious disease being the predominant
causes of mortality [1]. Immunosuppressive therapy may
potentiate traditional pre-transplant risk factors [2], but
cannot fully explain the increased long-term mortality after
renal transplantation [3].
Hyperglycaemia is reported to be a risk marker for CVD
and cancer among healthy individuals without diabetes [4,
5]. Post-challenge hyperglycaemia is particularly associated
with increased all-cause, cardiovascular (CV) and cancer
mortality in the general population [5–7]. The impact of
hyperglycaemia on patient survival after renal transplanta-
tion is, however, unknown. Some studies indicate an
association between post-transplant diabetes mellitus
(PTDM) and mortality [8–10], whereas others do not [11,
12]. Renal transplant recipients may have normal fasting
plasma glucose (fPG) but at the same time elevated 2 h
plasma glucose (2hPG). Only half of individuals with new-
onset diabetes after renal transplantation are identified from
an fPG ≥7.0 mmol/l [13], as compared with 70% in the
general population [14] and 80% in morbidly obese persons
[15]. In addition, approximately one out of five recipients
has impaired glucose tolerance (IGT) or impaired fasting
glucose (IFG) 10 weeks after renal transplantation [16].
Thus, performing an OGTT in the early post-transplant
period may be important for the identification of renal
transplant patients with hyperglycaemia.
The aim of this study was to assess the long-term effects
of early post-transplant glycaemia on overall and cause-
specific mortality after renal transplantation.
Methods
Design and study population A total of 2,458 consecutive
patients received a renal transplant at our centre between
2 February 1995 and 19 October 2006. After the exclusion
of 1,048 patients because of re-transplantation, age
<18 years, early death, early graft loss, pre-existing diabetes
mellitus or failure to perform an OGTT, 1,410 patients were
included in this prospective cohort study (Fig. 1). The
participants were observed until either the primary endpoint
(death) was reached or 31December 2008 (median [range] 6.7
[0.3–13.8] years). Patients who developed PTDM (manifest
PTDM, n=58) before the scheduled OGTT did not complete
the test, while the remaining 1,352 first-time renal transplant
recipients underwent an OGTT 10 weeks (mean [SD] 71 [9]
n=2,033 
First time recipients 
n=2,123 
Renal transplant recipients 
n=2,458 
n=1,996 
n=1,928 
Prospective cohort study 
n=1,410 
Oral glucose tolerance test 
n=1,352 
n=1,602 
Manifest PTDM 
n=58 
Re-transplant recipients 
n=335 
Age <18 years 
n=90 
Death before baseline 
n=37 
Graft loss before baseline 
n=68 
Diabetes at Tx 
n=326 
Failure to perform an OGTT 
n=192 
Fig. 1 The number of patients receiving their first kidney transplant
without pre-existing diabetes mellitus at the time of transplantation
(Tx). Re-transplant recipients were excluded. Failure to perform an
OGTT denotes patients who were transferred to local hospitals before
the scheduled OGTT at baseline 10 weeks after renal transplantation.
Patients who developed manifest diabetes during the first 10 weeks
after transplantation (Manifest PTDM) did not undergo an OGTT. A
total of 1,410 patients were included in the prospective cohort study
and 1,352 patients underwent an OGGT
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days) after renal transplantation. The participants gave
informed consent and the study was approved by the
regional ethics committee and was performed in accordance
with the Declaration of Helsinki [17].
Glucose measurements The OGTT was performed after an
overnight fast with patients instructed not to eat or drink, to
refrain from smoking and not to take any medication less
than 8 h before the test. Each patient drank 75 g of
anhydrous glucose dissolved in 250 ml of water. Blood
samples were drawn at 0 and 120 min. From May 1995 to
August 1996, glucose was measured in serum using a
glucose dehydrogenase method (Cobas Mira, Roche, Basel,
Switzerland). From September 1996 until December 2006
venous whole blood glucose was measured using the
Hemocue AB B-glucose Analyzer, Angelholm, Sweden.
The glucose measurements are presented as plasma (serum)
glucose [18]. Plasma glucose was calculated by multiplying
whole blood glucose with the constant factor of 1.11 [19].
Assessment of diabetes and glycaemia The current ADA
criteria were used to classify patients into the following
glucose categories: PTDM, fPG ≥7.0 mmol/l or 2hPG
≥11.1 mmol/l; IFG, fPG 5.6–6.9 mmol/l and 2hPG
<7.8 mmol/l; IGT, fPG <7.0 mmol/l and 2hPG 7.8–
11.0 mmol/l; and normal glucose tolerance (NGT), fPG
<5.6 mmol/l and 2hPG <7.8 mmol/l [20]. Patients were
also categorised as either post-challenge hyperglycaemia
defined as a 2hPG ≥7.8 mmol/l or normoglycaemia
defined as a 2hPG <7.8 mmol/l [20].
Immunosuppressive therapy Our immunosuppressive pro-
tocol has been described previously [13]. In summary, the
standard protocol from February 1995 to January 2000
consisted of prednisolone, ciclosporin A, azathioprine, and
thereafter the protocol included prednisolone, ciclosporin A
and mycophenolate. In most instances, tacrolimus was
given if ciclosporin A was withdrawn because of rejection,
toxicity or side effects.
Data registration and endpoints The following baseline
data were collected 10 weeks after renal transplantation:
recipient age, sex, BMI, fPG, 2hPG, HbA1c, serum creatinine,
Cr-EDTA-measured glomerular filtration rate, serum lipids
and immunosuppressive medication. Friedewald’s equation
was used to calculate LDL-cholesterol. We searched the
Norwegian Renal Registry [21] and the DataCor database
[22] to identify patients with pre-transplant CVD. Patients
were classified as having pre-transplant CVD if they
had: suffered a CV event (myocardial infarction, angina
pectoris, stroke/transient ischaemic attack or claudica-
tion); or had undergone a revascularisation procedure
(percutaneous coronary intervention or coronary artery
bypass graft surgery) or surgery on pre-cerebral arteries
or for peripheral vascular disease. Data on smoking
habits, pre-transplant renal status and hypertension were
collected from the Norwegian Renal Registry [21].
According to National Kidney Foundation Disease Out-
come Quality guidelines, hypertension was defined if patients
were using anti-hypertensive therapy within the first post-
transplant year or had a systolic blood pressure ≥140 mmHg
or a diastolic blood pressure ≥90 mmHg. Patients who did not
receive pre-transplant dialysis were encoded as pre-emptive
transplantation. Early cytomegalovirus (CMV) infection was
diagnosed in patients with at least one positive test for either
CMV-pp65 antigen in leucocytes or CMV-PCR in plasma
before baseline [23].
The study outcomes were all-cause and cause-specific
mortality after renal transplantation as defined by the
European Renal Association–European Dialysis and Trans-
plant Association causes of death codes: CV 11–18 and 21–
29; infection 31–43; malignancy 66–67; other diagnoses
(43–46, 51–53, 61–64, 69–73, 81–82); and unknown (0)
[24]. Nephrologists at 24 centres annually report data on all
Norwegian patients undergoing renal replacement therapy
to the Norwegian Renal Registry [21], from which numbers
and causes of deaths were retrieved. The numbers of death
were cross-checked with the official Norwegian National
Registry and the causes of death were encoded by
experienced local nephrologists.
Missing data Some variables in the data set had missing
data: hypertension (32%), smoking status (27%), total
cholesterol (10%), height (3%), weight (3%), creatinine
(3%) and CMV infection (1%). To compensate for missing
data, multiple imputation was used to generate ten iterations
for the variables with missing data, each containing 1,410
complete cases [25]. Both complete and incomplete
variables were used as predictors during the imputation
process. The variables used for multiple imputation
included: age, sex, donor age, donor status (living or
deceased), height, weight, creatinine, use of ciclosporin A,
early CMV infection, early hepatitis C virus infection, total
cholesterol, fPG, 2hPG, HbA1c, early rejection, hyperten-
sion, primary diagnosis of renal disease (glomerulonephritis,
pyelonephritis, polycystic kidney disease, nephrosclerosis,
other diagnoses), pre-transplant renal status (haemodialy-
sis, peritoneal dialysis, pre-emptive transplantation), hu-
man leucocyte antigen (HLA)-DR mismatch (none, one,
two), smoking status (never, former or current), cause of
death (CVD, malignancy, infection, other, unknown),
survival time (months). Variables not normally distributed
were logarithmically transformed (fPG, 2hPG and creati-
nine). Statistical analyses were first performed on each
imputed data set, and thereafter pooled to achieve a single
variable estimate.
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Statistical analyses Non-imputed descriptive data are pre-
sented as mean (SD) or frequency (%). The 1,352 patients
who underwent the OGTT were dichotomised to have post-
challenge hyperglycaemia (2hPG ≥7.8 mmol/l) or normo-
glycaemia. Differences between groups were analysed
using independent samples t test for continuous data and
Fisher’s exact test for categorical data. Associations
between fPG and 2hPG were analysed using non-
parametric correlations (Spearman’s ρ). Kaplan–Meier plots
and logrank test were used to analyse crude cumulative
survival for the various ADA categories.
Hazard ratios and corresponding 95% CIs were estimated
using Cox proportional hazard regression models. Glycaemia
was included as either a continuous explanatory variable or a
categorical variable. Continuous explanatory variables were
fPG and 2hPG. Categorical variables were: NGT=reference;
IFG; IGT; PTDM; and post-challenge hyperglycaemia,
yes/no. Patients with manifest PTDM (n=58) before the
scheduled OGTT were included only in the analyses with
glucose categories as explanatory variables. Also, an
interaction term between fPG and 2hPG was included.
We fitted three multiple Cox regression models. In
model 1 we adjusted for age and sex. In model 2 we
further adjusted for traditional risk factors: BMI; creatinine;
pre-transplant CVD; total cholesterol; hypertension; and
smoking status [1–3, 10]. In model 3 we included
additional adjustments for transplant-related risk factors:
donor status; pre-emptive transplantation; CMV infection;
early rejection; and usage of ciclosporin A [2, 3, 11]. The
assumption of linearity was assessed by fitting multifrac-
tional models, which allows for several types of non-
linearity, and testing for the best fit [26].
Model discrimination between predicted and estimated
risk was assessed using Harrell’s concordance index
(c-statistic) [27, 28]. A result was considered to be
statistically significant when p<0.05. Statistical analyses were
conducted with the use of Stata 11.0 (StataCorp, College
Station, TX, USA) and PASW 18.0 (Chicago, IL, USA).
Results
Out of 1,410 recipients included in the prospective study, a
total of 638 (45%) had NGT, 217 (16%) had IFG, 313
(22%) had IGT and 242 (17%) had PTDM.
Demographic and clinical characteristics of the patients
who underwent an OGTT (n=1,352) according to the
presence or absence of post-challenge hyperglycaemia are
presented in Table 1. The recipients with a 2hPG
≥7.8 mmol/l were significantly older, had less favourable
kidney function and were more likely to have a history of
smoking, pre-transplant CVD, CMV infection and rejection
than those with 2hPG <7.8 mmol/l. Unadjusted all-cause
and CV mortality HRs of prevalent risk factors inherent to
the transplant population are presented in Table 2.
A total of 282 (20%) of the 1,410 recipients died during the
study period: 79 (12%) of the patients with NGT, 31 (14%) of
the patients with isolated IFG, 90 (29%) of the patients with
IGT, and 82 (34%) of the patients with PTDM (p<0.001). A
total of 120 (42%) patients died from CVD, 65 (23%) from
malignancy, 67 (24%) from infectious diseases, 17 (6%)
from other causes and 13 (5%) from unknown causes.
Septicaemia and bacterial pneumonia accounted for 57% and
31% of the infectious deaths, respectively.
Mortality according to glucose as a continuous variable Both
fPG and 2hPG were associated with increased all-cause and
CV mortality risk in the unadjusted Cox regression analyses
(Tables 3 and 4). After adjustments for confounders, the
impact of fPG became statistically non-significant, while
2hPG remained a significant predictor of overall mortality
risk (Table 3). In the multivariable cause-specific Cox
regression analyses, both fPG and 2hPG remained associ-
ated with increased risk of CV death (Table 4). The fPG
and 2hPG were correlated (r=0.59, p<0.001), but there was
no statistically significant interaction between fPG and
2hPG (p=0.527). When both 2hPG and fPG were included
in the multivariable model 3, only 2hPG was found to be a
predictor of all-cause mortality (2hPG, HR 1.05 [95% CI
1.00, 1.11] p=0.038; fPG, HR 0.97 [95% CI 0.84, 1.14]
p=0.740). For all the regressions analyses, a linear model
was the best fit for the continuous glucose measurements
(data not shown).
Mortality and glucose as categorical variables Cumulative
mortality according to glucose category is shown in Fig. 2.
The logrank test indicated a significant difference in
mortality between the subgroups (p<0.001). Recipients
with PTDM, IGT or post-challenge hyperglycaemia at
baseline had an approximately twofold unadjusted in-
creased death risk compared with those with NGT or post-
challenge normoglycaemia (Table 3). The overall mortality
risk was attenuated after multiple adjustments in Cox
models 1–3, but remained statistically significant in all the
multivariable analyses. Conversely, IFG failed to show any
association with mortality (Tables 3 and 4).
Table 4 shows that post-challenge hyperglycaemia was
associated with an approximately twofold increased risk of
death from CV disease, malignancy and infectious disease.
PTDM was associated with a nearly threefold increased
risk from CVD, while IGT was associated with a twofold
increased risk of infectious death. After multivariable
adjustments, PTDM remained associated with a twofold
increased risk of CV death, whilst post-challenge hyper-
glycaemia, but not IGT, remained associated with a nearly
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twofold highermortality risk from infectious disease (Table 4).
Including the various glucose variables into model 3 had
minimal effect on overall and CV mortality with an increase
in c-statistic of less than 0.01 (data not shown).
Of the 184 recipients with new-onset PTDM diagnosed
from an OGTT, 92 (50%) were diagnosed from an fPG
≥7.0 mmol/l and an equal number of patients were
diagnosed from an isolated 2hPG ≥11.1 mmol/l (n=92),
whereas 63 (34%) patients fulfilled both the criteria. Mean
fPG for recipients with an isolated 2hPG ≥11.1 mmol/l was
5.9 (0.69)mmol/l. Compared with recipients without
PTDM, the multi-adjusted HRs of recipients diagnosed
from fPG ≥7.0 mmol/l and 2hPG ≥11.1 mmol/l were
1.49 (95% CI 1.00, 2.23) and 1.22 (0.80, 1.86).
Discussion
The main finding of this large single-centre study of renal
transplant recipients was that as a predictor of long-term
mortality, post-challenge 2hPG measured early after renal
transplantation was superior to, and independent of, fPG,
even after adjustments for confounding risk factors. Each
1 mmol/l increment in 2hPG was associated with a 5%
(95% CI 1%, 9%) increased risk of death from any cause
and 6% (95% CI 1%, 12%) increased risk of death from CV
Table 2 Unadjusted HR risk estimates by Cox proportional regres-
sion analyses for all-cause and CV mortality
Variable Overall mortality CV mortality
HR (95% CI) HR (95% CI)
Age (years) 1.06 (1.05, 1.07) 1.07 (1.06, 1.09)
Male 1.31 (1.01, 1.69) 1.66 (1.09, 2.52)
BMI (kg/m2) 0.97 (0.94, 1.01) 1.01 (0.96, 1.06)
Creatinine (μmol/l) 1.00 (1.00, 1.01) 1.01 (1.00, 1.01)
Pre-transplant CVD 2.07 (1.59, 2.71) 2.56 (1.73, 3.79)
Total cholesterol (mmol/l) 1.01 (0.92, 1.10) 0.96 (0.84, 1.09)
Hypertension 0.66 (0.48, 0.92) 0.88 (0.46, 1.67)
Active or former smoker 1.17 (0.79, 1.74) 1.28 (0.71, 2.32)
Deceased donor 2.39 (1.83, 3.12) 2.77 (1.82, 4.23)
Pre-emptive transplantation 0.62 (0.46, 0.84) 0.58 (0.36, 0.93)
CMV infection 1.62 (1.26, 2.07) 1.91 (1.29, 2.84)
Early rejection 1.02 (0.81, 1.30) 1.31 (0.92, 1.88)
Use of ciclosporin A 1.83 (1.02, 3.27) 1.57 (0.69, 3.58)
Characteristic Total Post-challenge
normoglycaemia
(<7.8 mmol/l)
Post-challenge
hyperglycaemia
(≥7.8 mmol/l)
p value
n (%) 1,352 863 (64) 489 (36) –
Age (years) 51 (15) 49 (15) 55 (14) <0.001
Male, n (%) 892 (66) 564 (65) 328 (67) 0.550
BMI (kg/m2) 24.3 (3.6) 24.2 (3.5) 24.6 (3.7) 0.062
Obese (BMI ≥30 kg/m2), n (%) 87 (7) 51 (6) 36 (8) 0.300
Creatinine (μmol/l) 132 (41) 129 (36) 137 (47) 0.002
GFR (ml min−1 1.73 m−2) 53.7 (14.7) 54.5 (14.1) 52.0 (15.8) 0.006
Pre-transplant CVD, n (%) 216 (16) 116 (13) 100 (20) 0.001
Total cholesterol (mmol/l) 6.53 (1.50) 6.51 (1.45) 6.57 (1.59) 0.519
HDL-cholesterol (mmol/l) 1.55 (0.49) 1.59 (0.49) 1.46 (0.46) <0.001
Triacylglycerol (mmol/l) 2.14 (2.17) 2.03 (2.45) 2.38 (1.43) 0.008
LDL-cholesterol (mmol/l) 4.02 (1.53) 4.01 (1.61) 4.05 (1.36) 0.657
Hypertension, n (%) 745 (83) 487 (84) 258 (83) 0.925
Active or former smoker, n (%) 603 (61) 393 (57) 210 (69) 0.001
Deceased donor, n (%) 745 (55) 427 (50) 318 (65) <0.001
Months on dialysis 15 (13) 14 (14) 15 (11) 0.578
Pre-emptive transplantation, n (%) 328 (24) 214 (25) 114 (23) 0.553
CMV infection, n (%) 740 (55) 445 (52) 295 (61) 0.002
Early rejection, n (%) 490 (36) 277 (32) 213 (44) <0.001
Prednisolone dose (mg/day) 13.1 (5.2) 12.5 (4.6) 14.3 (6.0) <0.001
Use of ciclosporin A, n (%) 1,137 (90) 732 (90) 405 (90) 0.768
Ciclosporin A trough level (μg/l) 219 (76) 212 (73) 233 (81) <0.001
Use of tacrolimus, n (%) 124 (10) 78 (10) 46 (10) 0.767
Tacrolimus trough level (μg/l) 9.7 (3.3) 9.4 (3.3) 10.2 (3.2) 0.194
Table 1 Baseline characteristics
of the study population according
to post-challenge glycaemia
Data are given as mean (SD) or
frequency (%)
p values denote differences be-
tween groups
LDL-cholesterol was calculated
using Friedewald’s equation
Pre-emptive transplantation
denotes patients who received a
kidney transplant before starting
dialysis
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Table 3 HRs estimated by Cox regression analyses for all-cause mortality according to plasma glucose (as categorical or continuous variables)
Variable Unadjusted HR (95% CI) Multivariable HR (95% CI)
Model 1 Model 2 Model 3
Glucose category
Normal glucose tolerance 1.00 1.00 1.00 1.00
Impaired fasting glucose 0.74 (0.49, 1.13) 0.77 (0.50, 1.17) 0.77 (0.51, 1.18) 0.79 (0.52, 1.23)
Impaired glucose tolerance 1.78 (1.32, 2.42)* 1.43 (1.05, 1.94)* 1.42 (1.05, 1.94)* 1.39 (1.01, 1.91)*
Post-transplant diabetes mellitus 2.03 (1.49, 2.77)* 1.51 (1.10, 2.07)* 1.54 (1.12, 2.13)* 1.54 (1.09, 2.17)*
p values for trend <0.001 0.001 0.002 0.006
Harrell’s concordance index 0.597 0.738 0.759 0.757
Level of 2hPG
Post-challenge normoglycaemia 1.00 1.00 1.00 1.00
Post-challenge hyperglycaemia 1.98 (1.55, 2.54)* 1.53 (1.19, 1.97)* 1.55 (1.21, 2.00)* 1.49 (1.15, 1.95)*
Harrell’s concordance index 0.583 0.737 0.755 0.759
fPG
fPG (mmol/l) 1.13 (1.03, 1.24)* 1.10 (1.00, 1.21) 1.12 (1.01, 1.24)* 1.11 (0.99, 1.24)
Harrell’s concordance index 0.538 0.734 0.750 0.755
2hPG
2hPG (mmol/l) 1.08 (1.05, 1.12)* 1.04 (1.01, 1.08)* 1.05 (1.01, 1.09)* 1.05 (1.01, 1.09)*
Harrell’s concordance index 0.594 0.742 0.754 0.757
Model 1 is adjusted for age and sex. Model 2 is additionally adjusted for traditional risk factors: BMI; creatinine; pre-transplant CVD; total
cholesterol; hypertension; and smoking status. Model 3 is additionally adjusted for transplant-related risk factors: donor status; pre-emptive
transplantation; CMV infection; early rejection; and use of ciclosporin A
*p<0.05
Table 4 HR estimated by Cox regression analyses for CV death, death from malignancy and from infectious disease according to plasma glucose
(as categorical or continuous variables)
Variable Unadjusted HR (95% CI) Multivariable HR (95% CI) (model 3)
CVD Malignancy Infection CVD Malignancy Infection
Glucose category
Normal glucose tolerance 1.00 1.00 1.00 1.00 1.00 1.00
Impaired fasting glucose 0.73 (0.37, 1.41) 0.94 (0.42, 2.08) 0.44 (0.16, 1.17) 0.76 (0.39, 1.49) 0.97 (0.42, 2.00) 0.50 (0.18, 1.37)
Impaired glucose tolerance 1.52 (0.93, 2.50) 1.73 (0.92, 3.25) 1.89 (1.05, 3.41)* 1.04 (0.62, 1.74) 1.37 (0.71, 2.64) 1.75 (0.92, 3.34)
Post-transplant diabetes mellitus 2.72 (1.73, 4.29)* 1.80 (0.93, 3.48) 1.45 (0.75, 2.82) 1.80 (1.10, 2.96)* 1.36 (0.65, 2.83) 1.37 (0.66, 2.86)
p values for trend <0.001 0.138 0.011 0.023 0.687 0.055
Harrell’s concordance index 0.627 0.572 0.595 0.782 0.736 0.816
Level of 2hPG
Post-challenge normoglycaemia 1.00 1.00 1.00 1.00 1.00 1.00
Post-challenge hyperglycaemia 2.00 (1.36, 2.93)* 1.79 (1.07, 2.97)* 2.07 (1.24, 3.46)* 1.34 (0.89, 2.00) 1.34 (0.78, 2.30) 1.91 (1.09, 3.33)*
Harrell’s concordance index 0.593 0.572 0.568 0.779 0.738 0.817
fPG
fPG (mmol/l) 1.21 (1.06, 1.37)* 1.17 (0.98, 1.40) 0.95 (0.75, 1.20) 1.19 (1.01, 1.39)* 1.16 (0.94, 1.44) 0.95 (0.73, 1.24)
Harrell’s concordance index 0.562 0.557 0.512 0.777 0.732 0.810
2hPG
2hPG (mmol/l) 1.11 (1.06, 1.16)* 1.05 (0.98, 1.13) 1.06 (1.00, 1.14) 1.06 (1.01, 1.12)* 1.01 (0.93, 1.09) 1.05 (0.97, 1.14)
Harrell’s concordance index 0.626 0.573 0.556 0.780 0.734 0.813
Model 3 is adjusted for age, sex, BMI, creatinine, pre-transplant CVD, total cholesterol, hypertension, smoking status, donor status, pre-emptive
transplantation, CMV infection, early rejection and use of ciclosporin A
*p<0.05
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disease. In addition, our findings are the first to indicate that
renal transplant recipients with IGT have lower long-term
chance of survival than those with NGT.
Glucose measurements as continuous variables This study
demonstrates an independent continuous relationship
between 2hPG and long-term mortality in a renal transplant
population without known diabetes. These findings are in
accordance with two previous community-based cohort
studies of non-diabetic persons of comparable age [6, 29].
Our results also partly support the findings from a
population-based prospective cohort of more than 10,000
adult men and women demonstrating a continuous positive
relationship between non-diabetic hyperglycaemia and
mortality [30]. In our study the association between fPG
and mortality became statistically non-significant after
adjustments for transplant-related risk factors. Some studies
have reported a J-shaped relationship between fPG as a
continuous variable and both overall and CV mortality,
whereas a linear relationship best described the association
between 2hPG and overall and CV mortality [30, 31]. We
cannot completely rule out the possibility that a non-linear
relationship between fPG and mortality might have influ-
enced the Cox proportional hazard risk. However, by fitting
our models using multifractional models, no non-linear
model outperformed a standard linear model in our sets of
data.
Post-challenge hyperglycaemia and glucose categories Re-
cipients with post-challenge hyperglycaemia, PTDM and
IGT had an increased overall mortality risk. Our findings
confirm the results of two large cohort studies that
demonstrated that PTDM, diagnosed by Medicare claims
or required treatment for hyperglycaemia, is associated with
reduced patient survival [8, 10]. We now extend this
conclusion to PTDM diagnosed by fasting glucose as well
as to PTDM and IGT diagnosed by an OGTT.
Our findings also concur with those from two large meta-
analyses addressing the impact of IFG and IGTonmortality in
non-transplant European populations that found that IGT is
superior to IFG in predicting all-cause and CV mortality and
from five Asian populations that found that IGT but not IFG
was associated with all-cause and CV mortality [7, 32]. In
contrast to the latter analysis, we diagnosed patients with
isolated IFG (fPG of 5.6–6.9 mmol/l) (excluding concomi-
tant IGT), which might have reduced the mortality risk in
this group. Nevertheless, IFG was not associated with death
after the inclusion of all recipients with an fPG of 5.6–
6.9 mmol/l in the present study (data not shown).
In further contrast with our study, the previous studies
implemented the criteria of the WHO for IFG (fPG 6.1–
6.9 mmol/l) [33]. However, our results were largely
unchanged when we reclassified the glucose categories
according to the WHO criteria (data not shown). Partly in
contrast with our findings, one large Australian prospective
study showed that both isolated IFG (WHO criteria) and
IGT were independent predictors of all-cause and CV
mortality [34]. Our findings indicate persons with increased
risk of death, but do not necessarily imply that lowering of
glucose excursions would reduce this risk. In a recently
published study of non-transplanted persons with IGT and
either established CVD or known risk factors for CVD, a
5-year period of treatment with nateglinide did not
influence the incidence of CVD. In this study, however,
the participants had a lower mortality risk as compared with
a transplant population.
Whether glucose-lowering therapy in renal transplant
recipients with either IGT or PTDM is associated with lower
long-term morbidity or mortality remains to be shown.
In the cause-specific analysis, PTDM was associated
with increased mortality from CVD whilst post-challenge
hyperglycaemia predicted increased mortality from infec-
tious disease. The reduction in deaths from infectious
disease is considered one of the major improvements in
short-term mortality outcome after renal transplantation
during the recent decades, and the predominant cause of
infection beyond 6 months post-transplant is bacterial rather
than viral [1]. In the present study, 90% of the infectious
deaths were caused by either bacterial pneumonia or
septicaemia. However, our finding of a possible relation-
ship between post-challenge hyperglycaemia and long-term
mortality from infectious diseases needs verification and
should be interpreted with care.
Strengths and limitations The inclusion of a large number
of consecutively included non-diabetic renal transplant
recipients at the single transplant centre in Norway reduced
the possibility of sample selection bias and increased the
internal validity of the study. Only 10% of the eligible
patients were unable to participate. The study population
Fig. 2 Cumulative mortality for recipients with NGT (solid black
line), IFG (dashed black line), IGT (dashed grey line) and PTDM
(solid grey line)
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consisted predominantly of white individuals, and thus the
results cannot be extended to populations of other ethnic-
ities. However, comparable results for PTDM have been
reported in two other studies that included individuals of
multiple races and ethnicities [8, 10].
The OGTT has poor reproducibility and a repeated test
diagnostic of diabetes is recommended by the current
guidelines [20]. However, according to the WHO an
epidemiological diagnosis of diabetes can be based on a
single OGTT or fPG [35]. Furthermore, although the OGTT
is more time consuming and has a higher intraindividual
coefficient of variance compared with fasting plasma
glucose, it is a more sensitive test for diagnosing PTDM
and IGT after renal transplantation [13, 36].
To account for missing data on hypertension (32%),
smoking status (27%) and total cholesterol (10%), we
performed ten iterations of multiple imputations. Also, the
prognostic effect of 2hPG on overall mortality was
attenuated after adjustment for age and sex, but was largely
unchanged after further adjustments for both traditional and
transplant-related risk factors. Thus, the imputed covariates
contributed little to the prognostic effect of early post-
transplant glucose levels on long-term mortality.
The estimated outcomes coincided with the observed
mortality in this study (multi-adjusted c-statistics: all-cause
>75% and CV mortality >77%). The additional effect of
including the various glucose variables in the multi-
adjusted models was, however, minimal. Nevertheless,
early post-transplant glycaemia remained an independent
predictor of both all-cause and CV mortality.
We used fPG and 2hPG as diagnostic criteria for
diabetes without including the recently introduced ADA
criteria of HbA1c ≥6.5% [20]. The diagnostic value of
HbA1c in patients with end-stage renal disease awaiting
renal transplantation is poor, possibly because of uraemia,
usage of erythropoietin and dialysis [37]. In the early post-
transplant period haemoglobin levels stabilise and normal-
ised levels of erythropoietin and haematocrit have been
reported as early as at 2 months post-transplant [38].
However, blood loss related to surgical procedures and
subsequent inflammation, immunosuppressant agents caus-
ing bone marrow suppression and abrupt cessation of
erythropoietin are among the factors that may affect HbA1c
levels early after kidney transplantation [38].The usage of
HbA1c as a diagnostic criterion might therefore not apply in
the early post-transplant period.
Conclusions
This study indicates that 2hPG, when measured early after
renal transplantation, is superior to fPG in predicting long-
term all-cause and CV mortality. It also demonstrates that
PTDM predicts both all-cause and CV mortality, whereas
IGT predicts all-cause, but not CV mortality and finally that
post-challenge hyperglycaemia predicts all-cause mortality
and death from infectious disease. Post-challenge hyper-
glycaemia may be a predictor of long-term outcome in renal
transplant patients, and an OGTT might provide a method
to identify renal transplant recipients with increased risk of
premature death.
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